COVER PAGE  
Official Title:  A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b  
Study of the Efficacy, Safety, and Tolerability of 6 -Week Extended  
Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With  
Relapsing -Remitting Multiple Sclerosis Switching From Treatment  
With [ADDRESS_406248] Interval Dosing (SID) in Relation  
to Continued SID Treatment - Followed by [CONTACT_59168] -Label Crossover  
Extension Study Comprising Subcutaneous and Intravenous  
Nata lizumab Administration  
Study ID: [REMOVED]  
Document  Date : Protocol version 4.0: [ADDRESS_406249]
Cambridge, MA  [ZIP_CODE]
[LOCATION_002]
PROTOCOL NUMBER: 101MS329 Biogen Idec Research Limited
Innovation House
[ADDRESS_406250]
Maidenhead Berkshire
SL6 4AY
[LOCATION_008]
PHASE OF DEVELOPMENT: 3b
PROTOCOL TITLE: A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b 
Study  of the Efficacy , Safety , and Tolerability  of 6-Week Extended I nterval Dosing (EI D) 
of Natalizumab (BG00002) in Subjects With Relapsing- Remitting Multiple Sclerosis 
Switching From Treatment With [ADDRESS_406251] Interval Dosing (SID) in 
Relation to Continued SID Treatment - Followed by  [CONTACT_328910] -Label Crossover Extension
Study Comprising Subcutaneous and Intravenous Natalizumab Administration
EUDRA CT NUMBER: 2018-002145-11
DATE: 20August [ADDRESS_406252] OF ABBREVIATION S
.....................................................................................15
3. SPONSOR I NFORMATION .....................................................................................17
4. INTRODUCTION ......................................................................................................18
4.1.
Overview of Multiple Sclerosis..................................................................................18
4.2.
Current Therapi[INVESTIGATOR_254090] ...................................................................19
4.3. Profile of Previous Experience With Natalizumab .....................................................19
4.3.1. Nonclinical Experience ...............................................................................................19
4.3.2.
Clinical Experience.....................................................................................................19
4.4. Benefit -Risk Assessment ............................................................................................20
4.5. Study  Rationale ...........................................................................................................21
5. SCHEDUL E OF ACTIVITI ES..................................................................................22
5.1. Part 1 
–Schedule of Activities ...................................................................................22
5.2. Part 2 
–Schedule of Activities ...................................................................................[ADDRESS_406253] to Follow -Up.......................................................................................................61
10.3. Withdrawal of Subjects From Study
...........................................................................61
11. STUDY TREATMENT USE .....................................................................................62
11.1. Regimen ......................................................................................................................62
11.1.1. Part 1 Regimen ...........................................................................................................62
11.1.2. Part 2 Regimen ...........................................................................................................62
11.2. Modification of Dose and Treatment Schedule ..........................................................62
11.2.1. Modification of Dose ..................................................................................................62
11.2.2. Modification of Treatment Schedule ..........................................................................62
[IP_ADDRESS]. Part 1 Modification of T reatment
................................ ................................ ............... 62
[IP_ADDRESS]. Part 2 Modification of Treatment ...............................................................................63
11.3. Precautions ..................................................................................................................63
11.4. Compliance .................................................................................................................63
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
511.5. Concomitant Therap y and Procedures ........................................................................63
11.5.1. Concomitant Therap y
.................................................................................................63
[IP_ADDRESS]. Allowed Concomitant Therap y...................................................................................63
[IP_ADDRESS]. Disallowed Concomitant Therap y
..............................................................................64
11.5.2. Concomitant Procedures .............................................................................................64
[IP_ADDRESS]. Disallowed Concomitant Procedures ..........................................................................64
11.6. Continuation of Treatment ..........................................................................................65
12. STUDY TREATMENT MANA GEMENT ................................................................66
12.1. Natalizumab ................................................................................................................66
12.1.1. Natalizumab Preparation ............................................................................................66
12.1.2. Natalizumab Storage ...................................................................................................66
12.1.3. Natalizumab Handling and Disposal ..........................................................................67
12.1.4. Natalizumab Accountability .......................................................................................67
13. EFFI CACY, PHARMACOKI NETIC, AND PHARMACOD YNAMIC 
ASSESSMENTS .........................................................................................................68
13.1. Clinical Efficacy  Assessments ....................................................................................68
13.1.1. Part 1 Efficacy  Assessments .......................................................................................68
13.1.2. Part 2 Efficacy  Assessments .......................................................................................69
13.2. Pharmacokinetic Assessments ....................................................................................69
13.3. Pharmacod ynamic Assessments .................................................................................69
13.3.2. Part 2 Pharmacod ynamic Assessments .......................................................................70
14.
SAFETY ASSESSMENTS ........................................................................................71
14.1. Clinical Safety  Assessments .......................................................................................71
14.2. Laboratory  Safet y Assessments ..................................................................................71
14.3. Natalizumab Safety  Assessments ................................ ................................ ............... 71
15. SAFETY DEFINITIONS, RECORDI NG, REPORTI NG, AND 
RESPONSIBILIT IES.................................................................................................72
15.1.
Definitions ................................ ................................ ................................ .................. 72
15.1.1. Adverse Event ................................ ................................ ................................ ............. 72
15.1.2. Serious Adverse Event ................................ ................................ ................................ 72
15.1.3. Prescheduled or Elective Procedures or Routinely  Scheduled Treatments ................ 73

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
615.2. Safety  Classifications ..................................................................................................73
15.2.1. Investigator Assessment of Events .............................................................................73
15.2.2. Relationship of Events to Study  Treatment ................................................................73
15.2.3. Severity  of Events .......................................................................................................74
15.2.4.
Expected ness of Events ..............................................................................................74
15.3. Monitoring and Recording Events ..............................................................................74
15.3.1. Adverse Events ...........................................................................................................74
15.3.2. Serious Adverse Events ..............................................................................................75
15.3.3.
Immediate Reporting of Serious Adverse Events.......................................................75
[IP_ADDRESS]. Deaths .........................................................................................................................[ADDRESS_406254] E SIZE ...........79
16.1. Efficacy .......................................................................................................................79
16.1.1. Analy sis Population ....................................................................................................79
16.1.2. General Methods of Analysis .....................................................................................79
16.1.3. Part 1 Statistical Analy sis................................ ................................ ........................... 79
[IP_ADDRESS]. Analy sis of the Primary  Endpoint in Part 1 ................................ ................................ 79
[IP_ADDRESS]. Primary  and Secondary  Estimands and Handling of Intercurrent Events in 
Part1...........................................................................................................................80
[IP_ADDRESS]. Analy sis of the Secondary  Endpoints in Part 1 ................................ .......................... 81
[IP_ADDRESS]. Subgroup Analy ses in Part 1 .......................................................................................82
16.1.4. Part 2 Statistical Analy sis...........................................................................................83

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
[IP_ADDRESS]. Analy sis of the Primary  Endpoint in Part 2 ................................................................83
[IP_ADDRESS]. Analy sis of the Secondary  Endpoint in Part 2 ............................................................83
16.2. Pharmacokinetics ........................................................................................................86
16.2.1. Analy sis Population ....................................................................................................86
16.2.2. Methods of Anal ysis...................................................................................................86
16.3. Pharmacod ynamics .....................................................................................................86
16.3.1. Analy sis Population ....................................................................................................86
16.3.2. Methods of Anal ysis...................................................................................................86
16.5. Safety ..........................................................................................................................87
16.5.1. Analy sis Population ....................................................................................................87
16.5.2. Methods of Anal ysis...................................................................................................87
[IP_ADDRESS]. Adverse Events ...........................................................................................................87
[IP_ADDRESS]. Clinical L aboratory  Results ........................................................................................88
[IP_ADDRESS]. Vital Signs ..................................................................................................................88
[IP_ADDRESS].
C-SSRS .......................................................................................................................88
16.6. Antigenicit y/Immunogenicity  Data ............................................................................[ADDRESS_406255] OF TABLES
Table 1:
Part 1 Schedule of Activities – SID............................................................................23
Table 2:
Part 1 Schedule of Activities – EID................................ ................................ ............ 28
Table 3: Part 2 Schedule of Activities – EID SC vs. I V OLE for Subjects Who 
Participated in Part 1................................ ................................ ................................ ...33
Table 4: Part 2 Schedule of Activities – EID SC vs. I V OLE for New Subjects .....................[ADDRESS_406256] OF FIGURES
Figure 1: Design for Study  101MS329 with Open- Label Extension ................................ ......... 48
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
91. SYNOPSIS
Protocol Title: A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b 
Study  of the Efficacy , Safety , and Tolerability  of 6-Week Extended 
Interval Dosing (E ID) of Natalizumab (BG00002) in Subjects W ith 
Relapsing-Remitting Multiple Sclerosis Switching From Treatment 
With [ADDRESS_406257] Interval Dosing (SID) in Relation 
to Continued SID Treatment -Followed b y anOpen -Label Crossover 
Extension Study  Comprising Subcutaneous and Intravenous
Natalizumab Administration
Protocol Number: 101MS329
Version Number: 4.0
Name [CONTACT_204922] y 
Treatment:BG00002 (natalizumab; Ty sabri®)
Study  Phase: 3b
Study  Indication: Relapsing
-remitting multiple sclerosis (RRMS)
Study  Rationale: Extending the dosing interval of natalizumab (e.g., to 6 weeks) has 
been practiced b y some physicians in anti -John Cunningham virus
antibody -positive patients with the intention of improving the 
benefit/risk of the treatment by  [CONTACT_328911] -dependent risk of 
progressi ve multifocal leukoencephalopathy  while maintaining 
efficacy . Whether extending the dosing interval of natalizumab can 
potentially  improve benefit/risk for some patients remains to be 
established as there are no prospective, randomized, controlled studies 
assessing the efficacy  of extended interval dosing (EID). This study  
aims to assess the following: the initial efficacy , safety , and tolerability  
of switching to EID (dosing interval every 6 weeks [Q6W ]) after at 
least [ADDRESS_406258] interval dosing (SID) 
[dosing interval every 4weeks (Q4W )]compared to the continuation of 
SID; and the long -term efficacy , safety , and tolerability  of EID when 
natalizumab is delivered by  [CONTACT_6567] (SC) or intravenous (IV) 
administration. Thisstudy has 2 parts.
Part 1 is a randomized, controlled, rater -blinded analy sis
designed to compare the efficacy , safety , and tolerability of 
natalizumab EID and SID outcomes .
Part 2 is a randomized open -label extension (OLE) designed to 
assess subject preference for SC natalizumab EI D treatment 
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
10and explore long -term efficacy , safety , and tolerability of EID.
Study  Objectives 
and Endpoints:Part [ADDRESS_406259] 12 months, in relation to continued SI D 
treatment, with the goal of estimating the difference between SID and 
EID, with high precision and a narrow 95% confidence interval, to 
support the tre atment decision based on individualized benefit/risk 
assessments.
The primary  endpoint that relates to this objective is the 
number of new or newl y enlarging T2 hyperintense lesions at 
Week 72.
Secondary  objectives and endpoints for Part 1 of the study  areas 
follows:
To evaluate additional relapse- based clinical efficacy  measures 
of natalizumab EID in subjects who have previously  been 
treated with natalizumab SI D for at least [ADDRESS_406260] relapse (relapses will be adjudicated by  [CONTACT_328912])
oAnnualized relapse rate at Week 72
To evaluate disability  worsening of natalizumab EID in 
subjects who have previously  been treated with natalizumab 
SID for at least 12 months, in relation to continued SI D 
treatment.
oTime to Expanded Disability  Status Scale (EDSS) 
worsening (confirmed after at least 24 weeks)
To evaluate additional magnetic resonance imaging 
(MRI) -lesion efficacy  measures of natalizumab EID in subjects 
who have previously  been treated with natalizumab SI D for at 
least 12 months, in relation to continued SI D treatment.
oNumber of new or newly enlarging T2 hyperintense lesions 
at Week 24 and Week 48
oNumber of new gadolinium (Gd) -enhancing and new 
T1hypointense lesi ons at Weeks 24, 48, and 72
To evaluate the safet y of natalizumab EI D in subjects who have 
previously  been treated with natalizumab SID for at least 
12months in relation to continued SID treatment.
Protocol 101MS329 Version 4.[ADDRESS_406261] dose of 
study  treatment in Part 1.
Part 2 
Study  duration for subjects enr olled in Part 2 after completing Part 1 
and for new subjects will be approximately  108 weeks, comprising the 
following : 
36-week period of IV Q6W treatment
48-week randomized crossover treatment period comprising 
24weeks SCQ6W and 24 week s IVQ6W
12-week follow -up period
Follow -
up safet y phone call 12 weeks after the follow -up 
period ([ADDRESS_406262] dose of stud y treatment)
The total duration of study  participation for subjects who participate in 
both Part [ADDRESS_406263] research organization
C-SSRS Columbia Suicide Severity Rating Scale
Ctrough trough serum concentration of natalizumab
DHA Directions for Handling and Administration
DNA deoxyribonucleic acid
EDSS Expanded Disability Status Scale
EID extended interval dosing
EOS end of study
ET early termination
FSH follicle stimulating hormone
GCP Good Clinical Practice
Gd gadolinium
Hep hepatitis
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
INEC Independent Neurology Evaluation Committee
IRT interactive response technology
IV intravenous(ly)
JCV John Cunningham virus
KM Kaplan-Meier
mAb monoclonal antibody
mITT modified intent to treat
MMRM mixed model of repeated measures
MRI magnetic resonance imaging
MS multiple sclerosis
D
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of 
Biogen MA Inc.
16OLE open -label extension
PBMC peripheral blood mononuclear cell
PBVC percentage of brain volume change
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PML progressive multifocal leukoencephalopathy
PPQ Patient Preference Questionnaire
PRO patient -reported outcome
Q4W every [ADDRESS_406264]
North Ry de, NSW 2113
Australia
For urgent medical issues in which the study  Medical Director should be contact[INVESTIGATOR_530], please refer 
to the Study  Reference Guide’s Official Study  Contact L ist for complete contact [CONTACT_3031].
Biogen may  transfer any  or all of its study -
related responsibilities to a contract research 
organization (CRO) and other third parties; however, Biogen retains overall accountability  for 
these activities.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of 
Biogen MA Inc.
184. INTRODUCTION 
Natalizumab is a recombinant humanized anti- α4 integrin antibod y, derived from a monoclonal 
antibody  (mAb) [AN100226m] raised against human α4 integr in. The murine mAb 
(AN100226m) was humanized by  [CONTACT_328913] -determining region grafting of the 
hypervariable region of the gene encoding AN100226m onto a human immunoglobulin G4 
framework, producing the humanized immunoglobulin G4/kappa antibody , natal izumab.
Natalizumab has been approved under the propriety name [CONTACT_328951]®and was licensed for use in 
relapsing forms of multiple sclerosis (MS) b y the [LOCATION_002] (US) Food and Drug 
Administration on 23 November 2004. Natalizumab was authorized in the US on 05 June 2006, 
in the European Union on 27 June 2006 (Austria, Belgium, Bulgaria, Croatia 
[15December 2008], Cyprus, Czech Republic, Denmark, Estonia, Finland, [LOCATION_009], German y, 
Greece, Hungary , Ireland, I taly, Latvia, Lithuania, Luxembourg, Malta, the N etherlands, Poland, 
Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the [LOCATION_008]), and in 
multiple other countries in the rest of the world (Algeria, Argentina, Australia, Azerbaijan, 
Bahrain, Bosnia and Herzegovina, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican 
Republic, El Salvador, Georgia, Guatemala, Honduras, Hong Kong, Iceland, I ndia, Israel, Japan, 
Jordan, Kazakhstan, Kuwait, Lebanon, Lib ya, Malaysia, Mexico, Morocco, New Zealand, 
Norway , Oman, Panama, Peru, Qatar, Russia, Serbia, Singapore, South Africa, South Korea, 
Switzerland, Sy ria, Taiwan, Tunisia, Ukraine, the United Arab Emirates, Uruguay , and 
Venezuela).
4.1. Overview of Multiple Sclerosis
MS is a progressive, degenerative disease of the central nervous s ystem (CNS) charac terized b y 
a variet y of clinical courses. Approximately 90% of patients present with epi[INVESTIGATOR_328896]  (exacerbations) separated by  [CONTACT_328914] (relapsing- remitting phase). A t ypi[INVESTIGATOR_328897] [ADDRESS_406265] patients, is eventually  followed b y a 
period of chronic progressi ve decline (secondary  progression), with increasing disability  and 
with or without exacerbations. Approximately  10% of patients will have progression from the 
onset of the disease (primary  progression), without acute exacerbations.
MS is an inflammatory  disease of the CNS characterized by  [CONTACT_328915] (lesions), 
which give rise to the clinical sy mptoms of the disease. Although lesions can occur throughout 
the CNS, certain sites seem particularl y vulnerable, such as the optic nerve, brainstem, spin al 
cord, and periventricular regions. Lesions are believed to occur when activated T ly mphocy tes 
cross the blood- brain barrier and, once in the parenchy ma, initiate a series of events leading to 
activation of endothelial cells, recruitment of additional ly mphocy tes and monocy tes, release of 
proinflammatory  cytokines, and subsequent demyelination [Ffrench -Constant 1994] .  
Trafficking of leukocy tes across the blood- brain barrier involves interaction of the cell adhesion 
molecule α4 integrin, expressed on l ymphocy tes and monocy tes, with its counter receptors 
vascular cell adhesion molecule 1 (VCAM -1) and fibronectin on brain endothelial cells. In 
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of 
Biogen MA Inc.
19particular, VCAM -1 is expressed on inflamed brain endothelial cells and on activated microglial 
cells, while fibronectin is expressed aroun d inflamed brain microvessels [Hartung 1995] .
Blockade of these cell adhesion interactions is assumed to either prevent trafficking of 
leukocy tes across the vascular endothelium, into parench yma tissue, and subsequently  into 
inflamed tissue; or prevent their ac tivation by  [CONTACT_328916]. It is believed that the 
clinical progression of MS is related to the dem yelination caused b y leukocyte injury to the 
myelin sheaths. Thus, inhibiting or preventing leukocy te entry  into the CNS and subsequent 
leukocy teactivation is expected to be of therapeutic benefit in MS.
4.2. Current Therapi[INVESTIGATOR_328898]: 
interferon 
glatiramer acetate
dimethy l fumarate
teriflunomide
alemtuzumab
fingolimod
ocrelizumab
cladribine
mitoxantrone
natalizumab
diroximel fumarate
siponimod
ozanimod
4.3. Profile of Previous Experience With Natalizumab
See the Investigator’s Brochure (IB) for detailed information on relevant nonclinical and clinical
studies.
4.3.1. Nonclinical Experience
Thepharmacology , pharmacokinetics (PK), and toxicology  of natalizumab have been 
characterized in nonclinical in vitro and in vivo experimental sy stems. Nonclinical studies are 
outlined in the accompanying natalizumab IB.
4.3.2. Clinical Experience
Natalizumab has b een used extensively  in relapsing -remitting multiple sclerosis (RRMS) and 
Crohn’s disease, both in clinical studies as well as in the postmarketing setting.
Protocol 101MS329 Version 4.[ADDRESS_406266] received natalizumab for Crohn’s disease in clinical 
studies and in the postmarke ting setting, respectively . Additionall y, subjects ha ve received 
natalizumab in clinical studies for rheumatoid arthritis ( 231 subjects), acute ischemic stroke 
(210 subjects), and multiple my eloma (6 subjects).
The efficacy  of natalizumab in subjects with relapsing forms of MS has been established in 
3contr olled studies: a Phase [ADDRESS_406267] on disability  
worsening and relapse rate and markedl y attenuates brain magnetic resona nce imaging (MRI) 
measures of inflammation and tissue destruction in subjects with relapsing forms of MS. 
Moreover, the data indicate that efficacy  is realized earl y and persists throughout the treatment 
period.
4.4. Benefit-Risk Assessment
After more than [ADDRESS_406268] 
on the quality  of life in patients with RRMS. I n pi[INVESTIGATOR_328899], natalizu mab 
demonstrated a 67% reduction in annualized relapse rate and a 42% reduction in the risk of 
disability  progression over [ADDRESS_406269]- line therapi[INVESTIGATOR_014] [Belachew 2011 ; Morrow 2010; Oturai 
2009; Sangalli 2011 ].
Extensive safety  data from clinical studies and the postmarketing setting have resulted in a 
well-characterized safet y profile for natal izumab. Infusion and hy persensitivity  reactions and 
anti-natalizumab antibody  production are important safet y concerns; however, they are 
manageable in routine clinical practice. Serious herpes infections and hepatic events are 
additional safet y concerns t hat are also included in product labeling; however, the incidence of 
these adverse events (AEs) is low.
The most important AE affecting natalizumab benefit- risk assessment is the occurrence of 
progressive multifocal leukoencephalopath y (PML). Three establi shed risk factors for the 
development of PML  have been identified and are currently  included in the product labeling: that 
PML  risk is increased with the presence of anti- John Cunningham virus (JCV) antibodies, 
treatment duration (especially  beyond 2 yearsof therap y), and prior use of an 
immunosuppressant therapy . These 3 risk factors, as well as information about anti -JCV 
antibody  index in anti -JCV antibody -positive patients without any  prior immunosuppressant use, 
can be utilized to further stratify  the risk of PML  and therefore provide an important tool for 
physicians and patients when making individual benefit-risk decisions regarding initiation or 
continuation of natalizumab therap y. 
Overall, the benefit- risk ratio for natalizumab in treating RRMS remains positive.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of 
Biogen MA Inc.
214.5. Study Rationale
The safet y and efficacy  of the currently  recommended dose (300 mg natalizumab administered 
intravenously  [IV]every  4weeks [Q4W] ) has been well established through clinical trials and in 
real-
world clinical practice.  
Exten ding the dosing interval of natalizumab (e.g., to every 6 weeks [Q6W] ) has been practiced 
by[CONTACT_328917] -JCV antibody -positive patients with the intention of improving the 
benefit/risk of the treatment by  [CONTACT_328911] -dependent risk of PML  while maintaining 
efficacy . In a prespecified, retrospective anal ysis of anti -JCV antibody -positive patients treated 
with natalizumab in the US TOUCH (Ty sabri®Outreach: United Commitment to Health) 
program (n = 18,755), the risk of PML  was compared b etween patients treated with standard 
interval dosing (SID) and patients treated with extended interval dosing (EID) for at least 
6months (300 mg with an average dosing interval of 5 to 6 weeks). The majority  of patients 
were treated with SI D for at least 1year before switching to EID (median of 25 SID infusions 
prior to switch). The analy sis demonstrated a clinically  and statistically  significant reduction in 
the risk of PML  in patients treated with EID. Whether extending the dosing interval of 
natalizum ab can potentially  improve benefit/risk for some patients remains to be established as 
there are no prospective, randomized, controlled studies assessing efficacy  of EID.
This study  will be conducted in 2 parts: Part 1 is a randomized, controlled, rater -
blinded, 
analysis designed 
to assess the efficacy , safet y, and tolerability of switching to EID ( Q6W 
dosing) after at least 12 months of disease stability  on SID ( Q4W dosing) ;Part 2 is 
a randomized
open -label extension (OLE )designed to assess preference for SC natalizumab EID treatment and 
explore long -term efficacy , safet y, and tolerability of EID.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy S tudy of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
23Table 1: Part 1 Schedule of Activities –SID
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed as follows:
, 2) clinical and neurological assessments, , and 4) dose administra tion. 
It is not required that all screening tests and assessments be completed during 1 visit.
Study WeekScreening
Visit1
-6 to -1Baseline 
Visit
04 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 722Follow 
Up 
EOS 
Visit
84Follow 
Up 
Safety 
Phone 
Call
963ET 
Visit4Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment )5
Study Day-42 to -1 0 28
(-2/
+5)56
(-2/
+5)84
(-2/
+5)112
(-2/
+5)140
(-2/
+5)168
(-2/
+5)196
(-2/
+5)224
(-2/
+5)252
(-2/
+5)280
(-2/
+5)308
(-2/
+5)336
(-2/
+5)364
(-2/
+5)392
(-2/
+5)420
(-2/
+5)448
(-2/
+5)476
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
Informed Consent 
Form  X
Eligibility Criteria 
CheckX X
Randomization X
Medical History X
Physical 
ExaminationX X6X X X X X X
Body  Weight X X6X X X X X X
Vital S igns7X X X X X X X X X X X X X X X X X X X X X X X
HIV, Hep B, and 
Hep C TestingX

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
24Study WeekScreening
Visit1
-6 to -1Baseline 
Visit
04 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 722Follow 
Up 
EOS 
Visit
84Follow 
Up 
Safety 
Phone 
Call
963ET 
Visit4Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment )5
Study Day-42 to -1 0 28
(-2/
+5)56
(-2/
+5)84
(-2/
+5)112
(-2/
+5)140
(-2/
+5)168
(-2/
+5)196
(-2/
+5)224
(-2/
+5)252
(-2/
+5)280
(-2/
+5)308
(-2/
+5)336
(-2/
+5)364
(-2/
+5)392
(-2/
+5)420
(-2/
+5)448
(-2/
+5)476
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
C-SSRS8X X X X X X X X X X X X X X X X X X X X X X X
EDSS X X X X X X X
Neurological 
Examination (MS 
Signs & Symptom s)X X X X X X X
Blood Hematology9X X X X X X
Blood Chemistry10X X X
Serum Pregnancy 
Test11 X
Serum FSH12X
Urine Pregnancy 
Test13 X

Protocol 101MS329 Version 4.[ADDRESS_406270] experiences signs and symptoms suggestive of liver injury (such as jaundice, vomiting, anorexia, nausea, fatigue, and right upper abdominal 
discomfort), liver function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl tr ansferase, bilirubin, and 
albumin) must be performed at the local laboratory on an expedited basis.
11Required for women of childbearing potential. Results must be known prior to Day 0/Baseline.
12For postmenopausal subjects only.
13Required for women of childbearing potential. Follow-up testing throughout the study will be done at the discretion of the Inve stigator or as required by [CONTACT_49762]. In each case of delayed menstruation (over 1 month between me nstrual periods), a urine pregnancy test should be performed.
15The screening MRI must be performed at least [ADDRESS_406271]'s 
MRI is scheduled to occur <[ADDRESS_406272] MRI was 
performed within the previous 4 weeks. In the event of an early study termination for a pregnancy, a Gd-enhancing MRI should no t be conducted.
16Please refer to the Directions for Handling and Administration (DHA) located in the Study Reference Guide for details of postdo se observation requirements.
17Subjects should be contact[CONTACT_3012] [ADDRESS_406273] dose of study treatment to discuss if there has been any new deve lopment of any new 
neurological symptoms. PML or new neurological symptoms indicative of PML (e.g., new or sudden change in thinking, vision, bala nce, or strength 
persisting over several days) must be immediately reported as an SAE.P
Protocol 101MS329 Version 4.0
Phase 3b Efficacy S tudy of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
28Table 2: Part 1 Schedule of Activities –EID
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed as follows: , 
2)clinical and neurological assessments, , and 4) dose administration. I t is not required that all 
screening tests and assessments be completed during 1 visit.
Study WeekScreening 
Visit1
-6 to -1Baseline 
Visit
06 12 18 24 30 36 42 48 54 60 66 722Follow
Up EOS 
Visit
84Follow Up 
Safety 
Phone 
Call3
96ET 
Visit4Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment )5
Study Day-42 to -1 0 42
(-2/
+5)84
(-2/
+5)126
(-2/
+5)168
(-2/
+5)210
(-2/
+5)252
(-2/
+5)294
(-2/
+5)336
(-2/
+5)378
(-2/
+5)420
(-2/
+5)462
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
Informed Consent Form X
Eligibility Criteria Check X X
Randomization X
Medical History X
Physical Examination X X6X X X X X X
Body  Weight X X6X X X X X X
Vital Signs7X X X X X X X X X X X X X X X X X
HIV, Hep B, and Hep C 
TestingX
C-SSRS8X X X X X X X X X X X X X X X X X

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
29Study WeekScreening 
Visit1
-6 to -1Baseline 
Visit
06 12 18 24 30 36 42 48 54 60 66 722Follow
Up EOS 
Visit
84Follow Up 
Safety 
Phone 
Call3
96ET 
Visit4Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment )5
Study Day-42 to -1 0 42
(-2/
+5)84
(-2/
+5)126
(-2/
+5)168
(-2/
+5)210
(-2/
+5)252
(-2/
+5)294
(-2/
+5)336
(-2/
+5)378
(-2/
+5)420
(-2/
+5)462
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
EDSS X X X X X X X
Neurological Examination 
(MS Signs &Symptom s)X X X X X X X
Blood Hematology9X X X X X X
Blood Chemistry10X X X
Serum Pregnancy Test11X
Serum FSH12X
Urine Pregnancy Test13X

Protocol 101MS329 Version 4.[ADDRESS_406274] dose of study treatment, 
to be followed by a final EOS Visit at 12 weeks (± 10 days ) and the follow-up safety phone call at [ADDRESS_406275] within 5 days of the onset of symptoms. Relapses should be 
documented in the relapse assessment form. The maximum number of samples eligible for collection and analysis are 2 (1 for each  unscheduled visit). The 
samples will be named NW1 and NW2.
6If a screening test is performed within [ADDRESS_406276]’s standard of care on the same day as a study visit do not need to be repeated for the study if  Biogen has access to the 
information and data are recorded in the subject’s CRF. Vital signs taken on a study treatment day must be performed prior to st udy treatment administration.
8The “baseline/screening” C-SSRS must be completed at the Screening Visit; at all other visits, the “since last visit” C-SSRS mu st be used.
9Sample to be collected prior to dosing.
10If a subject experiences signs and symptoms suggestive of liver injury (such as jaundice, vomiting, anorexia, nausea, fatigue, and right upper abdominal 
discomfort), liver function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl t ransferase, bilirubin, and 
albumin) must be performed at the local laboratory on an expedited basis.
11Required for women of childbearing potential. Results must be known prior to Day 0/Baseline.
12For postmenopausal subjects only.
13Required for women of childbearing potential. Follow-up testing throughout the study will be done at the discretion of the Inve stigator or as required by [CONTACT_49762]. In each case of delayed menstruation (over 1 month between menstrual periods), a urine pregnancy test should be performed.
15The screening MRI must be performed at least [ADDRESS_406277]’s 
MRI is scheduled to occur < [ADDRESS_406278] dose of study treatment to discuss if there has been any new devel opment of any new 
neurological symptoms. PML or new neurological symptoms indicative of PML (e.g., new or sudden change in thinking, vision, bala nce, or strength 
persisting over several days) must be immediately reported as an SAE.P
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
325.2. Part 2 –Schedule of Activities
For subjects who completed Part1 treatment and enrolled in Part 2, the schedule of activities for 
Part 2 ( Table 3)does not differ for subjects randomized to SC /IV or IV/SCwith the exception of 
the order o ftreatment administration during the cro ssover period.
For new subjects enrolled in Part 2, the initial screening , inclusive of select assessments, differs 
from those subjects who participated in Part 1but is otherwise the same beginning at Week 78 
through the end of Part 2 (Table 4).
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
33Table 3: Part 2 Schedule of Activities –EID SCvs.IVOLE for Subjects Who Participated in Part 1
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed asfollows: , 
2)clinical and neurological assessments, 3) PK/PD  collection, and 4) dose administration. I t is not required that all 
screening tests and assessments be completed during 1 visit.
Study Week 78 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit2Unscheduled 
Visit 
(Neurological 
Worsening and 
Relapse 
Assess ment)3Follow -Up 
Safety 
Phone Call
1804
Study Day546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Informed 
Consent Form 
for Part 25----X ----
Eligibility 
Criteria Check 
for Part 25----X ----
Randomization X
Vital signs6X X X X X X X X X X X X X X X X
Physical 
Exam ination1 X X X X X X X
Body Weight1X X X X
C-SSRS1,7X
TSQM X X X

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
34Study Week 78 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit2Unscheduled 
Visit 
(Neurological 
Worsening and 
Relapse 
Assess ment)3Follow -Up 
Safety 
Phone Call
1804
Study Day546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
EDSS X X X X X X
Neurological 
Examination 
(MS Signs &
Symptoms)X X X X X X
Blood 
Hematology8 X X X X X X X
Blood 
Chemistry9 X X X X
Urine Pregnancy 
Test10
PD Assessments 
(whole blood)8 X X X X X X X X X X
PK Natalizumab 
Concentration 
(serum)8X X X X X X X X X X
Anti-
natalizumab 
Antibodies8X X X X X X
Brain MRI11X X X X

Protocol 101MS329 Version 4.[ADDRESS_406279]'s standard of care on the same day as a study visit do not need to be repeated for the study if Biogen has access to the 
inform ation and data recorded in the subject's CRF. Vital signs on a study treatment day must be performed prior to the administrat ion of study treatment.
7The Part 1 "baseline/screening" C -SSRS must be completed at the Part 1 screening Visit; at all other visi ts, the "since last visit" C -SSRS must be used.
8Sample to be collected prior to dosing.
9If a subject experiences signs and symptoms suggestive of liver failure (such as jaundice, vomiting, anorexia, nausea, fatigu e, and right upper abdominal 
discomfort), liver function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma -glutamyl transferase, bilirubin, and 
albumin) must be performed at the local laboratory on an expedited basis.
10Follow -up testing for w omen of childbearing potential throughout the study will be done at the discretion of the Investigator or as required by [CONTACT_1769]. In 
each case of delayed menstruation (more than 1 month between menstrual periods), a urine pregnancy test should be performed .
11All postbaseline MRIs are to be completed within a [ADDRESS_406280]'s MRI is scheduled to occur < 4weeks after the last dose of 
steroid treatment for relapse, the MRI should be rescheduled so it is performed either befor e the steroid treatment or between [ADDRESS_406281]’s choice.
14PPQ assessments at Week [ADDRESS_406282] be collected after study treatment administration.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
37Table 4: Part 2 Schedule of Activities –EID SC vs .IV OLE for New Subjects
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed as follows: , 
2)clinical and neurological assessments, 3) PK/PD  collection, and 4) dose administration. I t is not required that all 
screening tests and assessments be completed during 1 visit. This Schedule of Activities is identical to the Schedule in Table 3 after 
the Week 84 visit.
Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assess ment)4Follow -
Up Safety 
Phone 
Call5
180
Nominal
Study Day-42to
-1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Informed 
Consent Form 
for Part 21X
Eligibility 
Criteria Check 
for Part 21X X
Randomization X
Medical 
History1 X
Physical 
Exam ination1 X X X X X X X X X
Body Weight1X X X X X X
Vital signs6X X X X X X X X X X X X X X X X X X
HIV, Hep B, 
and Hep C 
TestingX
TSQM X X X X

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
38Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assess ment)4Follow -
Up Safety 
Phone 
Call5
180
Nominal
Study Day-42to
-1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
EDSS X X X X X X X
Neurological 
Examination 
(MS Signs &
Symptoms)X X X X X X X
Blood 
Hematology7 X X X X X X X X
Blood 
Chemistry8,7 X X X X X
Serum 
Pregnancy Test9 X
Serum FSH10X
Urine Pregnancy 
Test11 X
PD Assessments 
(whole blood)7 X X X X X X X X X X X
PK Natalizumab 
Concentration 
(serum)7X X X X X X X X X X X

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written conse nt of Biogen MA Inc.
39Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assess ment)4Follow -
Up Safety 
Phone 
Call5
180
Nominal
Study Day-42to
-1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Anti-
natalizumab 
Antibodies7X X X X X X X
Brain MRI12X X X X X
Natali zumab 
EID IV infusionX X X X X X X
Natalizumab 
EID SC -IV 
Crossover13X X X X X X X X X14
PPQ15X X X
Safety (AEs, 
SAEs)Record as per Section 15.[ADDRESS_406283] as per Section 11.5 of the protocol X
Assessment of 
New 
Neurological 
Symptoms16X
AE=adverse event; CRF = case report form; EDSS = Expanded Disability Status Scale; EID = extended interval dosing; EOS =end of study;  
; ET =early termination; FSH = follicle stimulating hormone; Gd = gadolinium; Hep = hepatitis; HIV = human immunodeficiency virus; 

Protocol 101MS329 Version 4.[ADDRESS_406284] dose of study treatment to discuss if there has been any new development of neurological 
symptoms. PML or new  neurological symptoms indicative of PML (new or sudden change in thinking, vision, balance, or strength persisti ng over several 
days) must be immediately reported as a SAE.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
43

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
45To evaluate drug preparation and 
administration time between SC and IV 
routes of natalizumab administration.Mean time for drug preparation and 
administration.
To evaluate the safet y and immunogenicit y of 
SC versus IV routes of natalizumab 
administration.All endpoints will be assessed between
6months of SC and 6 months I V in the 
randomized, crossover period.
The proportion of subjects with 
treatment emergent AEs
The proportion of subjects who develop 
anti-natalizumab antibodies 
To evaluate the efficacy  of SC versus IV 
routes of natalizumab administration.All endpoints will be assessed between
6months of SC and 6 months I V in the 
randomized, crossover period.
Number of new or newly enlarging 
T2hyperintense lesions
Time to first relapse
Annualized relapse rate
Change in EDSS score
Number of new Gd- enhancing lesions
Number of new T1 hypointense lesions
PBVC and change in cortical and 
thalamic brain region volume
To characterize PK and PD of SC versus IV 
routes of natalizumab administration.All endpoints will be assessed between
6months of SC and 6 months I V in the 
randomized, crossover period.
Ctrough
Trough α4 integrin saturation

Protocol 101MS329 Version 4.[ADDRESS_406285] assignment. Approximately  
480 subjects are expected to be enrolled at approximately  100 sites in North America, Europe, 
and Australia. Subjects will be randomly
 assigned to continue to receive natalizumab in 1 of the 
following 2 groups:
SID:  approximately  240 subjects will receive natalizumab as a 300 mg IV infusion 
every  4weeks (28 [-2/+5 day s]).
EID:  approximately  240 subjects will receive natalizumab as a 300 mg IV infusion 
every  6weeks (42 [-2/+5 day s]). 
Randomization will be stratified b y countr y/region (North America [includes [LOCATION_003] and Canada], 
[LOCATION_008], Europe and Israel [includes Belgium, [LOCATION_009], [LOCATION_013] , Israel, Ital y, 
Netherlands, and Spain], and Australia), bod y weight ( ≤ 80 kg versus > 80kg), and duration of 
natalizumab exposure ( ≤ 3years versus > 3years). Subjects will receive open -label natalizumab 
at their assigned frequency  throughout the [ADDRESS_406286] not to participate ,in Part 2 will enter a 
12-week follow -upperiod , and will receive a 
follow -up safet y phone call 12weeks later (i.e., [ADDRESS_406287] dose of study  treatment ) 
before completing the study .
Part [ADDRESS_406288] 12 months , may  also be enrolled in Part 2 as n
ewsubjects
to ensure adequate sample size for the Part 2 analysis.
Subjects enrolled in Part 2 will receive natalizumab 300 mg b y IV infusion once every  6 weeks 
(42±7 day s)for a period of [ADDRESS_406289]’s choice , proceed to the 12-week follow -upperiod , and receive 
a follow -up safet y phone call 12 weeks later (i.e., [ADDRESS_406290] dose of study  treatment ) 
before completing the study .
The design of this study , inclusive of Parts [ADDRESS_406291] s who do not partici pate in Part 2 
will be up to 102 weeks .
This comprises a screening period of up to 6 weeks ;a treatment period 
of 72 weeks ;a follow -up period of 12 weeks ; and a follow -up safet y phone call 12 weeks after 
the follow -up per iod (i.e., [ADDRESS_406292] dose of study  treatment ).
The end of stud y (EOS) date for a subject in Part [ADDRESS_406293] protocol -specified assessment ;if the subject has ongoing AEs that are 
being followed, then the date may  be the date of AE resolution.
7.1.2. Study Duration for Subjects Enrolled in Part 1 and Part 2
The total duration of study  participation in Part 1 for subjects who also participate in Part 2 will 
be up to 78weeks ,compris inga screening period of up to 6 weeks and the randomized SI D or 
EID treatment period of 72 weeks .
The total duration of study  participation in Part 2for these subjects will be approximately  
108weeks . T his comprises EIDIV treatment for 36 weeks; a randomized EID SCvs.EID IV
crossover treatment period of 48 weeks; a follow- up period of 12 weeks; and a follow -up safet y 
phone call 12 weeks after the follow -up period (i.e., [ADDRESS_406294] dose of study  
treatment).  The total duration of study  participation for subjects who participate in both Part [ADDRESS_406295] protocol - specified assessment; if the subject has ongoing AEs 
that are being followed, then the date may be the date of AE resolution.
7.2. Responsibilities of Study Site Staff
7.2.1. General Staff Responsibilities During Part [ADDRESS_406296] in Part 1 and Part 2, the Investigator of the study  site will designate the 
following stud y site staff:
A primary  and backup unblinded treating neurologist
An unblinded treating nurse (or stud y coordinator; may be performed b y treating 
neurologist)
A primary  and backup blinded examining neurologist
A blinded examining technician (may  be performed by  [CONTACT_328918]) (see Section 7.2.2 for changes in Part 2)
An unblinded MRI technician
An unblinded pharmacist (or unblinded authorized designee)
Protocol 101MS329 Version 4.[ADDRESS_406297] will be responsible for the fol lowing:
Management of the routine neurological care of the subject, including the phy sical 
examination, management of treatment, and associated safet y monitoring.
Assessment (including assignment of causality ) and treatment of AEs, SAEs, and MS 
relapses.
Assessing whether the subject’s study
 treatment should be discontinued as per the 
criteria detailed in Section 10.
The treating neurologist may  designate the backup treating neurologist or the treating 
nurse at the stud y site to perform some of the tests an d evaluations listed under 
“treating neurologist.” If there is more than [ADDRESS_406298] as backup for each other.
Review of hematology  and blood chemistry  data from the central laboratory  to aid in 
the management of the subject. As with other laboratory  and clinical information, 
these data should NOT be reviewed b
y the examining neurologist, the backup 
examining neurologist, or the examining technician.
The primary  treating nurse (or stud y coordinator; may be performed b y treating neurologist) will 
be responsible for the following:
Assisting the treating neurologist in subject management, including the treatment of 
AEs, the 
treatment and assessment of disease relapses, and the recording of 
AEs/SAEs and concomitant medications.
Administering the PROs (TSQM,  
Collecting blood samples.
Obtaining vital signs.
The examining neurologist will be responsible for the following:
Obtaining an EDSS score and MS signs and s ymptoms based on a detailed
neurological examination at the scheduled timepoints required in the protocol.
Obtaining an EDSS score at every  unscheduled N eurological Worsening and Relapse 
Assessment Visit, if referred b y the treating neurologist when there is the possibility  
of a relapse.
The following guidelines must be strictly  followed:

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
52If an examining technician has to be replace d, the new examining technician must 
undergo a training session prior to performing an y study  assessment. 
The MRI technician will be responsible for the following:
Performing a brain MRI  scan with and without contrast, in accordance with the 
study -specifi c MRI manual, at all protocol- required timepoints.
The unblinded pharmacist (or unblinded authorized designee) will be responsible for the 
following:
Receipt, storage, distribution, and accountability  of study  treatment.
Storage and security  of documentati on related to study  treatment, dose preparation, 
and study  treatment assignment. All treatment assignment or study  treatment 
preparation information must be maintained strictly  confidential from the examining 
neurologist and examining technician at all times. Measures to prevent inadvertent 
unblinding must be followed.
Preparation of study treatments for IV infusion.
7.2.2. Changes in Responsibilities During Part [ADDRESS_406299] should return to the study  site for an 
unscheduled visit and be evaluated as soon as possible (within 5 days after onset of the event) for 
confirmation and to determine the severit y of the relapse. Relapses will be documented in the 
relapse assessment form.
An MS relapse will be defined as the onset of new or recurrent neurological sy mptoms lasting at 
least 24 hours, accompanied by  [CONTACT_328919] a neurological examination, and 
not explained solely  by [CONTACT_105]-MS processes such as fever, infection, severe stress, or drug toxicity  
(adapted from [Schumacher 1965 ]).
The Unscheduled Visit for Neurological W orsening and Relapse Assessment should not modify  
or replace the subjects’ visit schedule. If a subject’s study  MRI is scheduled to occur < 4weeks 
after the last dose of steroid treatment for relapse, the MRI  should be rescheduled so that it is 
performed either before the steroid treatment or between [ADDRESS_406300] dose of 
steroid treatment. MRI does not need to be performed at the ET Visit if the previous MRI  was 
performed within the previous 4 weeks.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
53New or recurrent neurological sy mptoms t hat occur < [ADDRESS_406301] then be reviewed and confirmed by  
[CONTACT_328920] (see Section 19.2.2). Treatment 
of a protocol -defined relapse may  proceed at the discretion of the Investigat or prior to INEC 
confirmation according to local standard of care and will not affect the subject’s eligibility  to 
continue in the study
. At the discretion of the Investigator, treatment may  include 
methy lprednisolone 1000 mg IV administered daily  for 3 to 5 day s with or without an oral
prednisone taper (up to 15 day s).
7.3.2. Unscheduled Visits in Part [ADDRESS_406302] meet the following eligibility  criteria 
at the time of randomization, or at the timepoint specified in the individual eligibility  criterion 
listed:
1.Ability  of the subject to understand the purpose and risks of the study  and provide signed 
and dated informed consent and authorization to use confidential health information in 
accordance with national and local subject privacy regulations.
2.Aged 18 to 60 years old , inclusive, at the time of informed consent.
3.Diagnosis of RRMS according to the McDonald criteria [Thompson 2018] .
4.Treatment with natalizumab as disease -modify ing monotherapy  for RRMS that is 
consistent with the approved dosing for a minimum of [ADDRESS_406303] 11 doses of natalizumab in the 12 months prior to 
randomization with no missed doses in the 3 months prior to randomization.
5.EDSS score ≤ 5.[ADDRESS_406304] at 
the time of randomization, or at the timepoint specified in the individual criterion listed:
1.Primary -and secondary -progressive MS.
2.MRI  positive for Gd -enhancing lesions at Screening.
3.Subjects for whom MRI  is contraindicated (e.g., have a contraindicated pacemaker or 
other contraindica ted implanted metal device, have suffered, or are at risk for, side effects 
from Gd, or have claustrophobia that cannot be medicall y managed).
4.History  of any  clinicall y significant (as determined by  [CONTACT_737]) cardiac, 
endocrinologic, hematologic, h epatic, immunologic, metabolic (including diabetes), 
urologic, pulmonary , neurologic (except for RRMS), dermatologic, psy chiatric, renal, or 
other major disease that would preclude participation in a clinical study , in the opi[INVESTIGATOR_15960].
5.History of human immunodeficiency  virus or positive test result at Screening, or history  
of other immunodeficient conditions. The requirement for testing at Screening may  be 
omitted if it is not permitted by  [CONTACT_427].
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
556.Known history  of hepatitis C (tes t for hepatitis C virus antibody ) or hepatitis B virus (test 
for hepatitis B surface antigen and/or hepatitis B core antibod y).
7.History  of malignant disease, including solid tumors and hematologic malignancies (with 
the exception of basal cell and squamous cell carcinomas of the skin that have been 
completely  excised and are considered cured).
8.History  of transplantation or any  antirejection therapy .
9.History  of severe allergic or anaphy lactic reactions or known hy persensitivity  to an y 
antibody  drug therap y.
10.A clinically  significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) 
within 30 days prior to Screening, or PML  or other opportunistic infections at any  time.
11.Presence of anti -natalizumab antibodies at Screening.
12.Signs or s ymptoms suggestive of any  serious infection, based on medical history , 
physical examination, or laboratory  testing, as determined by  [CONTACT_737].
Treatment History
13.Prior treatment with cladribine, mitoxantrone, T -cell or T -cell receptor vaccination, 
cyclophosphamide, cy closporine, azathioprine, methotrexate, or my cophenolate mofetil.
14.Prior treatment with an y therapeutic mAb other than natalizumab within 24 months prior 
to randomization.
15.Prior treatment with total ly mphoid irradiation.
16.Prior treatment with IV immunoglobulin, plasmapheresis, or cy tapheresis within 
12months prior to randomization.
17.Treatment with IV or oral corticosteroids (topi[INVESTIGATOR_328900]) or related products (e.g., Acthar®) within 3 months prior to rand omization.
Miscellaneous
18.History  of drug or alcohol abuse within 2 years prior to entry , per Investigator judgment.
19. Current enrollment or a plan to enroll in any  interventional clinical study  in which an 
investigational treatment or approved therap y for in vestigational use is administered 
within 30 days (or 5 half-lives of the agent, whichever is longer) prior to the Baseline 
Visit or at any  time during this study .
20.Inability  to compl y with study requirements.
21.Other unspecified reasons that, in the opi[INVESTIGATOR_328901], make the 
subject unsuitable for enrollment.
22.Women who are pregnant or breastfeeding, and women intending to become pregnant 
during the stud y.
Protocol 101MS329 Version 4.[ADDRESS_406305] meet the 
following eligibility  criteria at the timepoint specified in the individual eligibility  criterion listed:
1.Ability  of the subject to understand the purpose and risks of the study  and provide signed 
and dated informed co nsent for Part [ADDRESS_406306] at the timepoint specified in the individual criterion listed:
1.Subject treated with natalizumab 
EID was reverted to natalizuma b SID by [CONTACT_328921] 1.
2.Subject received treatment with any  MS disease- modify ing therapy  other than 
natalizumab in Part 1 or in the period between Part 1 and Part 2.
3.History  of any  clinicall y significant (as determined by  [CONTACT_57748]) cardiac, 
endocrinologic, hematologic, hepatic, immunologic, metabolic (including diabetes), 
urologic, pulmonary , neurologic (except for RRMS), dermatologic, psy chiatric, renal, or 
other major disease that would preclude participation in a clinica l study , in the opi[INVESTIGATOR_15960].
4.History  of human immunodeficiency  virus or history  of other immunodeficient 
conditions. 
5.History  of malignant disease, including solid tumors and hematologic malignancies (with 
the exception of basal cell and squamous cell carcinomas of the skin that have been 
completely  excised and are considered cured).
6. Current enrollment or a plan to enroll in any  interventional clinical study  in which an 
investigational treatment or approved therap y for investigational use is administered 
within 30 day s (or 5 half -lives of the agent, whichever is longer) prior to the Baseline 
Visit or at any  time during this study .
7.Inability  to compl y with study requirements.
8. Other unspecified reasons that, in the opi[INVESTIGATOR_328901], make the 
subject unsuitable for enrollment.
9.Women who are pregnant or breastfeeding, and women intending to become pregnant 
during the stud y.
8.5. Part [ADDRESS_406307] provide informed consent before any  screening tests are performed (see 
Section 17.3) . Participating stud y sites are required to document all screened candidates initially 
considered for inclusion in the study .
Screen failures are defined as subjects who sign the informed consent form (I CF) but are not 
subsequently randomized
. If a subject is considered a screen failure, the reasons for exclusion 
must be documented in the subject’s source documents and on the screening log. A minimal set 
of screen failure information is required to ensure transparent reporting of screen failure 
participants to meet the Consolidated Standards of Reporting Trials publishing requirements and 
to respond to queries from regulatory authorities. Minimal information includes demography , 
screen failure details, eligibility  criteria, and any  SAEs. Subjects who fail sc reening due to 
clinically  nonsignificant laboratory  result(s) or transient infection can be rescreened once, at the 
discretion of the Investigator
.
It is not required that all screening tests and assessments be completed during 1 pretreatment 
visit; however, some tests and assessments must be completed immediatel y prior to subjects 
receiving their last prestudy  dose of natalizumab. Other assessments can occur an ytime between 
the subjects receiving their last prestudy  dose of natalizumab and baseline ( see Section 5).
Participating stud y sites are required to document all screened candidates initially  considered for 
inclusion in the study . If a subject is excluded from the study , the reasons for exclusion will be 
documented in the subject’s source docume nts and on the screening log. A minimal set of 
screening failure information is required to ensure transparent reporting of screening failure to 
meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to 
queries from regu latory  authorities. Minimal information includes demography , screening failure 
details, eligibility  criteria, and any  SAEs.
9.1.2. Part [ADDRESS_406308] provide informed consent before any  Part 2 assessments are performed ( see 
Section 17.3). Participatin g stud y sites are required to document all screened candidates initially 
considered for inclusion in the study .
New subjects enrolling in Part [ADDRESS_406309] to screening as described in Section 9.1.1. New subjects w ho fail 
screening due to a clinically  nonsignificant laboratory  result(s) or transient infection can be 
rescreened once at the discretion of the Investigator.
Part 2 
Screening Visit will be performed during the Week 72 visit if possible or within 6 weeks 
prior to Week 78 or Week 84, whichever visit/infusion is the first Part [ADDRESS_406310] .
Subjects who meet Part 2 inclusion/exclusion criteria and provide informed consent will be 
enrolled and will receive t
heir first Part [ADDRESS_406311] does not continue in the study .
Randomization will be performed using interactive response technology  (IRT). Subjects will be 
randomized to receive natalizumab SI D or natalizumab EID in a 1:1 ratio. The randomization 
will be stratified by  [CONTACT_328922]/region (North America [includes [LOCATION_003] and Canada], United 
Kingdom, Europe and Israel [includes Belgium, [LOCATION_009], [LOCATION_013] , Israel, I taly, Netherlands, and 
Spain], and Australia), body  weight ( ≤80 kg versus > 80 kg), and duration of natalizumab 
exposure (≤ 3 years versus > 3 years).
Refer to the Study  Reference Guide for details on randomization.
9.2.2. Part 2 Randomization
Subjects will be randomized in a 1: 1 ratio, stratified by [CONTACT_328923] 1 (SID, 
EID, new subjects) to receive SC/I V orIV/SC before the first dose of crossover treatment in 
Part2 of the study .
9.3. Blinding Procedures
9.3.1. Part [ADDRESS_406312], and examining technician 
will be blinded to treatment assignments; however, the 
subjects, Investigator, Biogen, and 
IQVIA will know the subject’s treatment assignment. The central MRI rater will remain blinded 
throughout the stud y. To maintain the rater blinding, it is imperative that subject treatment 
assignments, infusion dates, and laboratory  data are not shared with the examining neurologist, 
backup examining neurologist, or examining technician.
9.3.2. Part [ADDRESS_406313] permanently  discontinue study  treatment for any  of the following reasons:
The subject becomes pregnant. Stud y treatment must be discontinued immediatel y. 
Report the p regnancy  according to the instructions in Section 15.4.2.
The subject develops persistent anti -
natalizumab antibodies (2 consecutive readings).
The subject develops PML or another serious opportunistic infection.
The subject withdraws consent to continue study  treatment.
The subject experiences an AE or SAE that necessitates permanent discontinuation of 
study  treatment.
The subject experiences hy persensitivity  or suspected allergic reaction to study  
treatment.
The subject experiences a medical emergency  that necessitates permanent 
discontinuation of study  treatment.
The subject is unwilling or unable to compl y with the protocol.
At the discretion of the Investigator for medical reasons.
At the discretion of the Investigator or Sponsor for noncompliance.
The primary  reason for discontinuation of study  treatment must be recorded in the subject’s case 
report form (CRF).
In Part 1, s ubjects who discontinue treatment may  remain in the study  and continue 
protocol -
required tests and assessments. Of note, subjects wh o discontinue natalizumab do not 
need to return for visits at which only vital signs and Columbia Suicide Severity  Rating Scale 
(C-SSRS )assessments are performed. Subjects who discontinue natalizumab should continue 
visits at 12- week interval s(e.g., Weeks 12, 24, 36, 48, 60, and 72).
If a subject chooses to withdraw from the stud y, an Earl y Termination (ET) Visit should occur as 
soon as possible but no later than [ADDRESS_406314] dose of study  treatment; in addition, all 
EOS assessments should be conducted at a separate EOS visit 12 weeks (± 10days) after the 
final dose of stud y treatment is received. A follow -up safet y phone call will be performed 
24weeks after the last dose of study  treatment.
In Part 2, subjects who discontinue study treatment will be required to withdraw from the study . 
If a subject chooses to withdraw from the study , an ET Visit should occur as soon as possible but 
no later than [ADDRESS_406315] dose of stud y treatment . In addition, all EOS assessments 
should be conducted at a separate EOS Visit 12 weeks (± 10days) after the final dose of study  
treatment. A follow -up safet y phone call will be performed 24weeks after the last dose of study  
treatment.
Protocol 101MS329 Version 4.[ADDRESS_406316] fails to return to the study  site for a required 
study  visit:
1.The study  site must attempt to contact [CONTACT_328924]/or should continue in the study .
2.In cases in which the subject is deemed lost to follow -up, the Investigator or designee 
must make every  effort to regain contact [CONTACT_1155]. These contact [CONTACT_254114]’s medical records.
3. Should the subject continue to be unreachable, that subject will be considered to have 
withdrawn from the study with a primary  reason of lost to follow -up.
10.3. Withdrawal of Subjects From Study
Subjects must be withdrawn from the stud y for any one of the following reasons:
The subject withdraws consent.  
The subject enrolls into another interventional clinical study  in which an 
investigational treatment or approved therap y for investigational use is administered.
The subject is unwilling or unable to compl y with the protocol.
The subject discontinues study  treatment in Part 2.
The primary  reason for the subject’s withdrawal from the study must be recorded in the subject’s 
CRF.
Subjects must undergo an ET Visit unless withdrawal is due to death or withdrawal of consent.
Subjects who withdraw from the study  may not be replaced.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6211. STUDY TREATMENT USE
11.1. Regimen
Refer to and follow the DHA fornatalizumab IV infusion in both Parts 1 and 2 of the stud y; refer 
to the DHA for natalizuma bSC injection in Part 2 of the study .
11.1.1. Part 1 Regimen
Subjects will continue to receive natalizumab either SI D (300 mg IV infusion Q4W ) or EID 
(300 mg IV infusion Q6W ) for a period of 72 weeks.
11.1.2. Part 2 Regimen
Subjects will initially  receive natalizumab 300 mg IV Q6W beginning on Week 78.During the 
treatment 
period beginning on Week 108 , subjects will receive natalizumab 300 mg Q6W for 
24weeks by [CONTACT_328925] 300 mg by  [CONTACT_328926] 24weeks in a randomized 
crossover
11.2. Modification of Dose and Treatment Schedule
11.2.1. Modification of Dose
The dosage of natalizumab cannot be modified.
11.2.2. Modification of Treatment Schedule
[IP_ADDRESS]. Part [ADDRESS_406317] 
24weeks, at the Investigator’s discretion:
Two or more new or enlarging T2 hyperintense lesions of any  size, compared with a 
previous scan performed as part of this study .
An EDSS worsening compared with previous assessment and confirmed at least 
24weeks after the initial increase meeting an y of the following criteria:  1) an 
increase of ≥ 1.0 in EDSS as compared with previous assessment if previous EDSS 
was ≤5.5 and > 0; or 2) an increase of ≥ 1.5 in EDSS if previous EDSS was 0; or 3) 
an increase of ≥0.5 in EDSS if previous EDSS was ≥
6.0.
A clinical relapse with new or recurrent neurological sy mptoms, not associated with 
fever or infection, having a minimum duration of 24 hours and an y of the foll owing:  
1) an increase of ≥1 grade in ≥ 2 functional scales of the EDSS; or 2) an increase of 
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
63≥ 2grades in 1 functional scale of the EDSS; or 3) an increase of ≥1 in the EDSS if 
the previous EDSS was ≤ 5.5, or ≥ 0.5 if the previous EDSS was ≥6 (an incr ease of 
≥1.5 in EDSS if previous EDSS was equal to 0).
Subjects who receive rescue treatment with natalizumab SID should remain in the study  and 
follow the schedule of activities for SI D. Subjects who receive rescue treatment different from 
natalizumab SI D may  remain in the study  and follow the schedule of activities with exception of 
natalizumab administration. Note, for subjects who experience acute clinical relapse, high dose 
corticosteroid treatment as per local standard of care (up to 5 day s) for rela pse treatment may  be 
administered (see Section 7.3).
[IP_ADDRESS]. Part 2 Modification of Treatment
In Part 2, there will be no protocol
-defined rescue treatment; subjects who discontinue study  
treatment in Part [ADDRESS_406318]’s 
written consent and the subject’s last study  visit.
[IP_ADDRESS]. Allowed Concomitant Therapy
Concomitant treatment with any of the following is allowed so long as the exclusionary  criteria 
described in Section 8.2are observed:
Medications necessary  for the treatment of AEs.
4-aminopy ridine if used per label and maintained on a stable regimen for at least 
30days prior to r andomization and throughout the study .
Medications used to treat MS sy mptoms such as spasticity , bladder impairment, pain, 
fatigue, or depression.
Short courses of high- dose corticosteroids per local standard of care in the treatment 
of protocol -defined re lapse of MS disease (see Section 7.3).
Corticosteroids that are administered by  [CONTACT_254112] (e.g., topi[INVESTIGATOR_2855], inhaled).
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
64In Part 2 only , corticosteroids administered via sy stemic routes (e.g., oral, injected, 
andintravenous) are also allowed.
[IP_ADDRESS]. Disallow ed Concomitant Therapy
Subjects should be instructed to contact [CONTACT_328927], 
including nonprescription drugs and herbal preparations.
Concomitant treatment with any  of the following is not allowed while receiving s tudy treatment, 
unless as otherwise described in this protocol:
Any nonstudy  treatments directed toward the treatment of MS such as chronic 
immunosuppressant therapy  or othe r immunomodulatory  treatments. This includes, 
but is not limited to interferon, glatiramer acetate, dimethy l fumarate, diroximel 
fumarate, cyclophosphamide, methotrexate, azathioprine, cladribine, mitoxantrone, 
IVimmunoglobulin, my cophenolate mofetil, fingolimod, siponimod, ozanimod, 
daclizumab, rituximab, ocrelizumab, or an y therapeutic mAb. 
Any investigational product, including investigational sy mptomatic therapi[INVESTIGATOR_254098] -MS indications.
In Part 1 only , systemic steroid therap y including, but no t limited to, oral 
corticosteroids (e.g., prednisone) or periodic (e.g., monthly ) treatment with IV 
methy lprednisolone, except for protocol
-defined treatment of relapses as described in 
Section 7.3.These therapi[INVESTIGATOR_328902] 2 only .
Subjects who receive an y of these restricted treatments may be required to discontinue study  
treatment 
permanently  and may  be withdrawn from the study  as outlined in Section 10.1.
11.5.2. Concomitant Procedures
A concomitant procedure is any  therapeutic interventi on (e.g., surgery /biopsy , phy sical therap y) 
or diagnostic assessment (e.g., blood gas measurement, bacterial culture) performed between the 
time of the subject’s written consent and the subject’s last study  visit, unless the subject is being 
followed up fo
r study -related toxicity .
[IP_ADDRESS]. Disallowed Concomitant Procedures
Treatment with an y of the following concomitant procedures is not allowed while receiving 
study  treatment, unless as otherwise described in this protocol:
total ly mphoid irradiation
T-cell or T -cell receptor vaccination
plasmapheresis
cytapheresis
Subjects who receive treatment with any  of these restricted procedures may  be required to 
permanentl y discontinue study  treatment and may  be withdrawn from the study  as outlined in 
Section 10.1.
Protocol 101MS329 Version 4.[ADDRESS_406319]’s 
CRF, according to the instructions for CRF completion. AEs related to the administration of 
these therapi[INVESTIGATOR_328903].
11.6. Conti nuation of Treatment
There is no provision to provide study  treatment after the study . Natalizumab is available 
commerciall y and subjects/I nvestigators can continue Ty sabri treatment via a commercial 
source. Once subjects have completed the Part [ADDRESS_406320] per local practice.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6612. STUDY TREATMENT MANA GEMENT
Study  treatment will be manufactured, handled, and stored in a ccordance with applicable Good 
Manufacturing Practice.
Study  site staff should follow the DHA for specific instructions on the handling, preparation, 
administration, and disposal of the study treatment. The DHA supersedes all other references 
(e.g., protoc ol).
Study  treatment must be dispensed only  by a pharmacist or appropriatel y qualified staff. Stud y 
treatment is to be dispensed only  to subjects enrolled in this study . Once study  treatment is 
prepared for a subject, it can be administered onl y to that subject. Study  treatments are for 
one-time use onl y; do not use any  study  treatment remaining in the vial for another subject.
12.1. Natalizumab
Natalizumab is a recombinant, humanized anti- α4 integrin antibod y manufactured b y Biogen.
Natalizumab for IV infusion i s supplied as a liquid in 15 mL vials containing 300 mg of 
natalizumab per vial and excipi[INVESTIGATOR_204880] (sodium phosphate monobasic monohy drate, 
sodium phosphate dibasic heptah ydrate, sodium chloride, and polysorbate 80).
Natalizumab for SC injection is pr ovided in a 1 mL prefilled s yringe containing 150 mg 
natalizumab and excipi[INVESTIGATOR_204880] (sodium phosphate, sodium chloride, poly sorbate 80, 
pH
6.0); [ADDRESS_406321] be stored in a secure location.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
67Natalizumab is to be stored at 2 C to 8 C (36 F to 46 F), protected from light, in a monitored 
and locked refrigerator with limited access. Study
 treatment is not to be frozen. For the most 
up-to-date storage requiremen ts, follow the instructions provided in the DHA.
12.1.3. Natalizumab Handling and Disposal
The Investigator must return all used and unused natalizumab study  treatment as instructed by  
[CONTACT_328928].
If any natalizumab supplies are to be destroy ed at the study  site, the institution or appropriate 
study  site staff must obtain prior approval from Biogen, b y providing, in writing, the destruction 
policy  or details of the method of destruction. After such destruction, Biogen must be noti fied, in 
writing, of the details of the study  treatment destroy ed (e.g., lot or kit numbers, quantities), the 
date of destruction, and proof of destruction.
12.1.4. Natalizumab Accountability
Accountability  for study  treatment is the responsibility  of the Investig ator. The study  site must 
maintain accurate records demonstrating the dates and amount of study  treatment received, to 
whom study  treatment was dispensed (subject -by-subject accounting), and accounts of an y study 
treatment accidentall y or deliberatel y dest royed or lost.
Unless otherwise notified, all study  treatment both used and unused must be saved for 
accountability . By [CONTACT_2054] , reconciliation must be made between the amount of 
natalizumab supplied, dispensed, and subsequently destroyed, los t, or returned to Biogen. A 
written explanation must be provided for an y discrepancies.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7114. SAFETY ASSESSMENTS
See Section 5for the timing of all safet y assessments.
14.1. Clinical Safety Assessments
The following clinical assessments will be performed to evaluate the safety  profile of 
natalizumab:
In Part 1 only :
C-SSRS
In Part 1 and for new subjects in Part 2 only ,
Medical history
In Part 1 and Part 2:
Physical examination
Body weight
Vital sign measurements: temperature, systolic and diastolic blood pressures, pulse 
rate, and respi[INVESTIGATOR_2842]
Concomitant therap y and procedure recording
AE and SAE recording
14.2. Laboratory Safety Assessments
Samples will be analy zed using Good Laboratory  Practice -validated assay sin Part 1 and Part 2.
The following laboratory assessments will be performed to evaluate the safety  profile of 
natalizumab:
Hematology : complete blood count with differential and platelet count and absolute 
neutrophil count
Blood chemistry : total protein, albumin, creatinine, blood urea nitrogen, uric acid, 
bilirubin (total and direct), alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, gamma
-glutamy l transferase, glucose, calcium, phosphorus, 
bicarbonate, chloride, sodium, and potassium 
14.3. Natalizumab Safety Assessments
The following assessments will be performed to determine the safet y of natalizumab in 
 Part 2:
Anti
-natalizumab antibodies


Protocol 101MS329 Version 4.[ADDRESS_406322] a causal relationship 
with this treatment. An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) produ ct, whether or not related to the medicinal (investigational) 
product.
Determination of whether an abnormal laboratory value and/or vital sign result meets the 
definition of an AE will be made b y the Investigator. Abnormal results are not considered AEs 
unless one or more of the following criteria are met:
The result meets the criteria for an SAE.
The result requires the subject to receive specific corrective therap y.
The result is considered by
 [CONTACT_254116].
15.1.2. Serious Adverse Event
An SAE is any  untoward medical occurrence that at any  dose:
Results in death
In the view of the Investigator, places the subject at immediate risk of death (a 
life-threatening event); however, this does not include an event that, had it occurred 
in a more severe form, might have caused death
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Results in a congenital anomaly /birth defect
Is a medicall y important even t
A medicall y important event is an AE that, in the opi[INVESTIGATOR_2511] I nvestigator, may  jeopardize the 
subject or may  require intervention to prevent one of the other outcomes listed in the definition 
above. (Examples of such medical events include allergic b ronchospasm requiring intensive 
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
73treatment in an emergency room or convulsions occurring at home that do not require an 
inpatient hospi[INVESTIGATOR_059].)
15.1.3. Prescheduled or Elective Procedures or Routinely Scheduled Treatments
A prescheduled or elective procedure or a routinely  scheduled treatment will not be considered 
an SAE, even if the subject is hospi[INVESTIGATOR_057]. The study site must document all of the following:
The prescheduled or elective procedure or routinely scheduled treatment was 
scheduled (or was on a waiti ng list to be scheduled) prior to obtaining the subject’s 
consent to participate in the study .
The condition requiring the prescheduled or elective procedure or routinel y scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_204884]’s consent to participate in the study  and the time of 
the procedure or treatment.
The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063].
oIf a subject is hospi[INVESTIGATOR_204885], the hospi[INVESTIGATOR_204886] 15.1.[ADDRESS_406323] be assessed to determine the following:
If the event meets the criteria for an SAE as defined in Section 15.1.2.
The relationship of the event to study  treatment as defined in Section 15.2.2
The severit y of the event as defined in Section 15.2.3 .
15.2.2.
Relationship of Events to Study Treatment
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study  treatment.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7615.3.4. Suspected Unexpected Serious Adverse Reactions
Suspe cted unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAEs that are unexpected and 
judged b y the Investigator or Biogen to be related to the study  treatment administered.
Biogen will report S[LOCATION_003]Rs to the appropriate regulatory  authorities and Investigator s as 
required, according to local law.
15.4. Procedures for Handling Special Situations
15.4.1. Progressive Multifocal Leukoencephalopathy
Due to the risk of PML in natalizumab- treated subjects, if neurological s ymptoms or MRI s 
indicate a possible pathology  other than M S, the following diagnostic procedures are 
recommended:
Careful evaluation of MRI , including comparison with previous MRI  scans.
 .
Timely  discontinuation of treatment.  If the Investigator is unable exclude PML  or 
other opportunistic infections (viral, bacterial, or fungal), natalizumab must be 
discontinued.
If, in the opi[INVESTIGATOR_689], a subject’s individualized risk for PML requires more 
frequent MRI monitoring than is performed as part of this study , additional MRI s to monitor for 
PML  may  be performed at the Investigator’s discretion.
15.4.2. Pregnancy
Subjects should not become pregnant after the first dose in this study and for at least 
[ADDRESS_406324] dose of study  treatment by  [CONTACT_328929] 24 hours of the study  site staff becoming aware of the pregnancy . Refer to 
the Study  Refe rence Guide’s Official Study  Contact L ist for complete contact [CONTACT_3031]. The 
Investigator or stud y site staff must report the outcome of the pregnancy to Biogen. A pregnancy  
is not considered an AE and should not be recorded in the AE CRF.
Congenital abnormalities and birth defects in the offspring of male or female subjects should be 
reported as an SAE if conception occurred during the study  treatment period.
15.4.3. Overdose
An overdose is an y dose of study  treatment administered to a subject or taken by  a sub ject that 
exceeds the dose assigned to the subject according to the protocol. Overdoses are not considered 
AEs and should not be recorded as an AE in the CRF; however, all overdoses must be recorded 
on an Overdose form and faxed to Biogen within [ADDRESS_406325] of care. The Investigator (or designee) should 
contact [CONTACT_43038] y’s Medical Director. Refer to the Study  Reference Guide’s Official Study  
Contact L ist for complete contact [CONTACT_3031].
15.5. Contraception Requirements
All women of childbearing potential must ensure that highl y effective contraception is used 
during the study and for at least [ADDRESS_406326] dose of study  treatment.
For the purposes of this study , women who do not meet one of the following criteria are 
considered to be ph ysiologically  capable of becoming pregnant and are, therefore, defined as 
women of childbearing potential:
Postmenopausal
o12 continuous months of natural (spontaneous) amenorrhea without an alternative 
medical cause 
o6weeks after surgical bilateral oophorectom y with or without hy sterectomy
Posthy sterectomy
Female surgical sterilization (e.g., bilateral tubal ligation)
For the purposes of the study , highl y effective contraception is defined as contraception that 
achieves a failure rate of < 1% when used consistently  and correctly , and includes the following:
For females:
Established use of oral, intravaginal, or transdermal combined (estrogen and progestogen 
containing) hormonal methods of contraception associated with the inhibition of 
ovula tion.
Established use of oral, injected, or implanted progestogen -only hormonal methods of 
contraception associated with the inhibition of ovulation.
Placement of an intrauterine device or intrauterine hormone-releasing s ystem.
Bilateral tubal occlusion.
True abstinence, when this is consistent with the preferred and usual lifest yle of the subject, can 
be considered an acceptable method of contraception based on the evaluation of the Investigator 
who should also take into consideration the duration of the clinical study . Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, postovulation methods) and withdrawal are not 
considered acceptable methods of contraception.
Pregnancy  reporting is described in Section 15.4.2 .
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7815.6. Safety Responsibilities
15.6.1. The Inv estigator
The Investigator’s responsibilities include the following:
Monitor and record all AEs, including SAEs, in the CRF regardless of the severit y or 
relationship to study  treatment.
Determine the seriousness, relationship, and severity  of each event.
Determine the onset and resolution dates of each event.
Monitor and record all pregnancies in female subjects and follow up on the outcome 
of all pregnancies.
Complete an SAE form for each SAE and fax it to Biogen within 24 hours of the 
study  site staff be coming aware of the event.
Pursue SAE follow- up information activel y and persistently. Follow -up information 
must be reported to Biogen within 24 hours of the study  site staff becoming aware of 
new information.
Ensure that all AE and SAE reports are suppor ted by  [CONTACT_71394]’ 
medical records.
Pursue AE follow -up information, if possible, until the event has resolved or become 
stable. Record AE follow -up information, including resolution, in the CRF, as 
applicable.
Report SAEs to local ethic s committees, as required by  [CONTACT_1769].
15.6.2. Biogen 
Biogen’s responsibilities include the following:
Before a stud y site can enroll any subjects, the Clinical Monitor is responsible for 
reviewing with study  site staff the definitions of AE and SAE, as well as the 
instructions for monitoring, recording, and reporting AEs and SAEs.
Biogen is to notify  all appropriate regulatory  authorities, central ethics committees, 
and Investigators of SAEs, as required b y local law, within the required time frames.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7916. STATISTICAL METHODS AND DETERMIN ATION OF 
SAMPLE SIZE
The objectives of the study  and the endpoints to be anal yzed are listed in Section 6.
In this more detailed description of the associated statistical methods, the endpoints are presented 
in relationship to 
categori cal assessment . The associated endpoint sof primary ,secondary , 
 importance are specificall y identified under each of these categor ies.
16.1. Efficacy
16.1.1. Analysis Population
The modified intent -to-treat (mITT) population , defined as all randomized subjects who receive 
at least [ADDRESS_406327] 1 postbaseline efficacy  assessment, will be 
used for all efficacy  analyses. Subjects will be analy zed in the groups to which they  are 
randomized.
16.1.2. General Methods of Analysis
Data will be collected and anal yzed in 2 parts:
1. After the completion of the randomized phase in Part 1, the primary  efficacy and safet y 
analyses will be performed. All data will be summarized by  [CONTACT_21964] 
(SID and EID).
2.After the completion of the 
randomized phase in Part 2, a nalyses of all Part [ADDRESS_406328] deviation , median, interquartile range, and overall range. For 
categorical endpoints, the summary  statistics will generall y include the number of subjects with 
available data a nd the percent ageof subjects with data in each category . 
In the anal ysis of Part 1 efficacy  variables, comparisons will be made between the EID group 
and theSID group.
16.1.3. Part 1 Statistical Analysis
[IP_ADDRESS]. Analysis of the Primary Endpoint in Part 1
The primary  endpoint, the number of new or newly  enlarging T2 hyperintense lesions at 
Week 72, will be anal yzed using negative binomial regression models with treatment as the 
classification variable and baseline bod y weight ( ≤80 kg versus > 80 kg), durat ion of 
natalizumab exposure at baseline ( ≤3 years versus > 3 years), and region (North America 
[includes [LOCATION_003] and Canada], [LOCATION_008], Europe, and Israel [includes Belgium, [LOCATION_009], 
German y, Israel, Italy, Netherlands, and Spain], and Australia) as cova riates. The ratio of mean 
lesion numbers of EID versus SID (EID/SID) will be derived from the model with a 95% CI and 

Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
80associated p- value. The treatment will be considered different if the lower limit of the 95% CI is 
above 1. As a secondary  inference, the possibility  of a 2 -fold increase in the mean lesion number 
in the EID group as compared with the SID group will be considered ruled out if the upper limit 
of 95% CI is no greater than 2. The proportion of subjects with no new or newly  enlarging 
T2hyperint ense lesions will be anal yzed using logistic regression models with the same 
covariates as those described above.
[IP_ADDRESS]. Primary and Secondary Estimands and Handling of Intercurrent Events in 
Part 1
The study  plans to make every  effort to retain subjects in the study  and to continue the follow -up 
in the cases with the initiation of rescue medication, switch to different dosing frequency , 
treatment discontinuation due to AEs, lack of efficacy , or for other reasons. This will allow 
continuing assessments of subjects’ MS disease activity . Efforts will also be made to obtain 
details of withdrawals in the generic categories of “lost to follow- up” or “other” whenever 
possible. Classification of the withdrawals in these nonspecific categories into “possibly  efficacy  
related,” “possibly  safet y-related ,” or “no information” will be made based on all available 
information by  [CONTACT_328930].
The proposed primary  estimand will be based on a treatment policy strategy, in which the stud y 
is intended to estimate the difference of a potential treatment decision of switching subjects from 
SID to EID compared with keepi[INVESTIGATOR_328904] [ADDRESS_406329] a “possibly  related” 
withdrawal, as described above, the missing values will be imputed by  [CONTACT_328931]. For withdrawals classified as “no 
information ,” the missing values will be treated as missing at random and will be addressed 
using multiple imputations. The number and proportion of subjects with intercurrent events and 
the time to intercurrent even
t will also be tabulated and compared between randomized groups. 
Sensitivity  analy sis may  be conducted using tippi[INVESTIGATOR_181417]. Supplementary  anal yses by  
[CONTACT_328932].
The secondary  estimand will be based on a hy pothetical strategy , in which the difference in the 
efficacy  of EID versus SID over the [ADDRESS_406330] -intercurrent event as missing values. For treatment discontinuation or 
switching due to efficacy as well as a withdrawal that is due to efficacy  or is “possibly  efficacy  
related ,” the mi ssing values will be imputed by  [CONTACT_328933]. For intercurrent events due to other reasons, the resulting 
missing values will be addressed using multiple imputations. Sensitivity  analy sis may  be 
conducted using tippi[INVESTIGATOR_328905].
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
83Country /region (North America [includes [LOCATION_003] and Canada], [LOCATION_008], 
Europe and Israel [includes Belgium, [LOCATION_009], [LOCATION_013] , Israel, Italy, Netherlands, and 
Spain], and Australia)
Baseline weight (40 to 59 kg, 60 to 79 kg, 80 to 89 kg, and ≥90 kg)
In addition, subgroup analy sis of the primary  and key  secondary  endpoints will be evaluated in 
subgroups defined by [CONTACT_328934], the number and t ype of ther api[INVESTIGATOR_328906], quartiles of the Ctrough values , and α -integrin saturation levels at Weeks 24, [ADDRESS_406331] dose 
administration during that period.
[IP_ADDRESS]. Analysis of the Prim ary Endpoint in Part [ADDRESS_406332] answer in the PPQ will be used to derive the primary  endpoint of 
Part2. The proportion of subjects preferr ing SCnatalizumab at the end of Part2 will be 
estimated, and the 
95% CI  will be calculated using the exact Binomial method. Additionally , the 
proportion of subjects preferring SC will be summarized by [CONTACT_328935] 2, 
i.e.,the group receiving SC followed by  [CONTACT_328936].
[IP_ADDRESS]. Analysis of the Secondary Endpoint in Part [ADDRESS_406333] ratio of relapse of SC versus IV (SC/IV) will be derived from the Cox model with a 
95% CI  and associated p
-value.
Annualized relapse rate
During each period of the crossover design in Part 2, all relapses reported prior to the end of each 
period will be included in the anal ysis for this endpoint.
The relapse rate for each route will be calculated as the total number of relapses experienced for
the administration route divided by  [CONTACT_312430] l number of subject- years on study at the end of each 
period for the route of administration. This is the unadjusted relapse rate.
In addition, the relapse rate for an individual subject will be calculated as the number of relapses
for that subject in each period divided by  [CONTACT_328937]. Based on these individual relapse rates, the mean and median for each route will 
be presented. This is called the subject relapse rate.
The annualized relapse rate at the end of each period will be analy zed using a negative binomial 
regression model ,with route of administration as the classification variable and the treatment 
arm during Part1 and period during Part2 as covariates. The logarithmic transformation of the 
number of years in the study  at the end of each period will be included in the model as the 
“offset” parameter. The ratio of mean annualized relapse rate of SC/IV will be derived from the 
model with a 95% CI  and associated p- value. If negative binomia l regression model does not 
converge, a Pois
son regression model with the same classification variable and covariates will be 
used instead.
Change in EDSS score
During each period of the crossover design in Part2, the change in EDSS score from the start 
date of a period to the end date of the same period will be calculated and summarized by  [CONTACT_328938].
Number of new Gd- enhancing lesions
The same method for the anal ysis of new or newly  enlarging T2 hy perintense lesions will be 
applied.
Number of new T1 hy pointense lesions
The same method for the anal ysis of new or newly  enlarging T2 hy perintense lesions will be 
applied.
PBVC and change in cortical and thalamic brain region volume
The same method for the anal ysis of new or newly  enlarging T2 hy perintense lesions will be 
applied.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
89covariates. The ratio of mean lesion numbers of EID versus SID (EID/SID) will be derived from 
the model with a 95% CI. The study  may  be stopped for futility  if the lower limit of the 95% CI 
is >2and a 2 -fold increase in mean lesion numbers in the EID group can be concluded with 
97.5% confidence.
In Part 2, no formal interim analy sis will be performed; however, there may be intermittent 
analyses of the data as needed.
16.8. Sample Size Considerations
Historical data on MS treatments, including a meta- analysis on the relationship between new or 
newly  enlarging T2 lesions and relapses, suggest little or no clinical relevance of a difference of 
0.2 to 0.3 in mean lesion numbers over 72 weeks [Sormani and Bruzzi 2013] .  With the planned 
sample size of N = 200/group, the prec ision of the estimated mean lesion numbers is sufficient to 
allow > 80% probability  to observe the lower limit of the 95% CI for the ratio of EID to SI D in 
the estimated mean lesion number above 1 if the true mean is 0.5 and 0.3 in the EID and SID 
group, r espectively . If the true mean is 0.6 and 0.3 in the EID and SID group, respectivel y, the 
probability  will be approximately  90%. In the other direction, the sample size provides a 
precision that allows approximately  90% probability  to observe the upper limi t of the 95% CI to 
be ≤2 if the true mean lesion numbers in both groups are 0.3. Approximately  480 subjects will 
be enrolled to account for a drop -out rate of approximately  17%.
For Part 2, in the absence of EID SC natalizumab data, it is assumed that the proportion of 
subjects who would prefer SC natalizumab is 75%, with a 7.5% margin of error; therefore, a 
sample size of 130 subjects for the95% CIs to be within 67.5% and 82.5 %. Approximately  
160subjects are needed to allow for 20% of subjects who do not provide an evaluable preference 
assessment (calculated by [CONTACT_328939] 7).
Protocol 101MS329 Version 4.[ADDRESS_406334] y with all instructions, regulations, and 
agreements in this protocol and applicable Internation al Council for Harmonisation (I CH) and 
Good Clinical Practice (GCP) guidelines and conduct the study  according to local regulations.
The Investigator is responsible for endorsing all data on completed CRFs electronicall y, prior to 
any interim lock or datab ase lock.
The Investigator may  delegate responsibilities for study -related tasks where appropriate to 
individuals sufficiently  qualified by  [CONTACT_8640], training, and experience, in accordance with 
applicable ICH and GCP guidelines. The Investigator should m aintain a list of the appropriatel y 
qualified persons to whom significant stud y-related duties have been delegated. The Investigator 
is responsible for supervising those individuals and for implementing procedures to ensure the 
integrit y of the tasks performed and an y data generated.
17.1. Declaration of Helsink i
This study  will be performed in alignment with the ethical principles outlined in the Declaration 
of Helsinki.
17.2. Ethics Committee
The Investigator must obtain ethics committee approval of the protocol, ICF, and other required 
study  documents prior to starting the stud y. Biogen or designee will submit documents on behalf 
of the study  sites in countries other than the US.
If the Investigator makes any  changes to the I CF, Biogen must approve the changes before the 
ICF is submitted to the ethics committee. A cop y of the approved ICF must be provided to 
Biogen. After approval, the I CF must not be altered without the agreement of the relevant ethics 
committee and Biogen.
It is the responsibility  of the I nvestigato rs to ensure that all aspects of institutional review are 
conducted in accordance with current applicable regulations.
Biogen must receive a letter documenting ethics committee approval, which specificall y 
identifies the protocol, protocol number, and ICF, prior to the initiation of the study . Protocol 
amendments will be subject to the same requirements as those in the original protocol.
A progress report must be submitted to the ethics committee at required intervals and not less 
than annuall y.
At the completion or termination of the study , the study  site must submit a close -out letter to the 
ethics committee and Biogen.
17.3. Subject Information and Consent
Prior to performing an y study-related activities under this protocol, including screening tests and 
assess ments, written informed consent with the approved ICF must be obtained from the subject 
Protocol 101MS329 Version 4.[ADDRESS_406335] (e.g., financial interest in 
Biogen) with the subject before the subject makes a decision to participate in th e study .
17.7. Registration of Study and Disclosure of Study Results
Biogen will register the study  and post -study  results regardless of the outcome on a publicly
accessible website in accordance with the applicable laws and regulations.
Protocol 101MS329 Version 4.[ADDRESS_406336] been processed correctly. Data anomalies will be communicated to the 
study  sites for clarification and resolution, as appropriate. The Investigator is responsible for 
endorsing all CRF data prior to an y interim or final database lock.
During and/or after completion of the study , quality  assurance officers named by  [CONTACT_328940] p erform onsite audits or inspections. The Investigator will be 
expected to cooperate with any  audit or inspection and to provide assistance and documentation 
(including source data) as requested.
18.3. Monitoring of the Study
The Investigator must permit study -related monitoring by  [CONTACT_71406]’ medical histories. Source data must be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data must be traceable, 
not obscure the origi nal entry , and be explained if necessary  (e.g., with an audit trail). The 
Investigator should maintain a record of the location(s) of essential documents.
The Clinical Monitor will visit the study site at regular intervals during the study  and after the 
study has completed, as appropriate. A clinical site monitoring plan will detail who performs the 
monitoring, how often, and the extent of review. It also will provide the monitoring strategy , 
with emphasis on subject safet y, data integrity, and critical dat a and processes.
During these visits, CRFs, supporting documentation, and essential documentation related to the 
study  will be reviewed, and any  discrepancies or omissions will be resolved. Documentation of 
results will be provided to Biogen in a timel y fashion to allow follow -up and verification of 
compliance with the monitoring plan. Remote evaluation of data (centralized monitoring) may  
also be conducted and reported as defined in the monitoring plan.
Monitoring visits must be conducted according to the applicable ICH and GCP guidelines to 
ensure the protection of subject rights and well -being, protocol adherence, quality  of data 
(accurate, complete, and verifiable), stud y treatment accountability, compliance with regulatory 
requirements, and continued ad equacy  of the study  site and its facilities.
18.4. Study Funding
Biogen is the Sponsor of the study  and is funding the study . All financial details are provided in 
the separate contracts between the institution, I nvestigator, and Biogen.
Protocol 101MS329 Version 4.[ADDRESS_406337] on paper forms and subsequently entered 
into the electronic CRF by [CONTACT_34450] y site staff.
19.1.4. Central Facility for MRI Scans
A cen tral MRI reader has been selected by  [CONTACT_328941] . All study  sites will need to perform a dummy  scan for the qualification of the study  site’s
MRI  machine; a separate I CF will be used for this scan. If there is a change in the MRI  machine 
during the stud y, this process will need to be repeated. The MRI central reader will be blinded to 
treatment allocation.
19.2. Study Committees
An Independent Data Monitoring Committee will not be used for this study because the 
Inves tigators and treating staff are not blinded to the subjects’ treatment assignment, natalizumab 
has a well -established safety  profile, and the study  has built- in rescue criteria and a futility  
analysis to check efficacy  failure.
19.2.1. Advisory Committee
An advisory  committee will be formed to provide scientific and medical direction for the stud y 
and to oversee the administrative progress of the study . The advisory  committee will meet at 
least annuall y to monitor subject accrual and to monitor compliance with the protocol at 
individual study sites. The advisory  committee will be blinded to subject treatment assignments.
Protocol 101MS329 Version 4.[ADDRESS_406338]. In this case, the appropriate regulatory  authorities will be notified subsequent 
to the modification.
In the event of a protocol modification, the I CF may  require similar modifications (see 
Section 17).
19.4. Ethics Committee Notification of Study Completion or Termination
Where required, the regulatory  authorities and 
ethics committees must be notified of the 
completion or termination of this study  and sent a copy  of the study  synopsis in accordance with 
the necessary  timelines.
19.5. Retention of Study Data
The minimum retention time for study  records will meet the strictest standard applicable to that 
study  site, as dictated b y any institutional requirements or local, national, or regional laws or 
regulations. Prior to proceeding with the destruction of records, the Investigator must notify
Biogen in writing and receive written authorization from Biogen to destro y study  records. In 
addition, the I nvestigator must notify  Biogen of any  changes in the archival arrangements 
including but not limited to archival at an offsite facility  or transfer of ownership if the 
Investigator l eaves the study  site.
19.6. Study Report Signatory
Biogen will designate one of the participating Investigators as a signatory  for the study  report. 
This determination will be made b y several factors, including but not limited to, the 
Investigator's experience a nd reputation in the studied indication; the I nvestigator’s contribution 
to the study  in terms of design, management, and/or subje ct enrollment; or by  [CONTACT_204921] n.
Protocol 101MS329 Version 4.0
Phase 3b Efficacy Study of Natalizumab EID After Switch From Natalizumab SID in Subjects With RRMS
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
9720. REFERENCES
Belachew S, Phan -Ba R, Ba rtholomé E, et al. Natalizumab induces a rapid improvement of 
disability  status and ambulation after failure of previous therapy  in relapsing -remitting multiple 
sclerosis. Eur J Neurol. 2011;18(2):240 -245.
Calabresi PA, Mellion M, Edwards KR, et al. Effica cy Results From the Phase 2b SYNERGY 
Study : Treatment of Disabling Multiple Sclerosis with the Anti -LING0 -1 Monoclonal Antibody  
Opi[INVESTIGATOR_328907]. Presented at the 2017 American Academy  of Neurology  Annual Meeting.
Ffrench -Constant C. Pathogenesis of multiple scl erosis. L ancet. 1994;343(8892):271-5.
Hartung HP, Archelos JJ, Zielasek J, et al. Circulating adhesion molecules and inflammatory 
mediators in demy elination: a review. Neurology . 1995;45([ADDRESS_406339] 6):S22- S32.
Morrow SA, O'Connor PW, Polman CH, et al. Evaluat ion of the s ymbol digit modalities test 
(SDMT) and MS neuropsy chological screening questionnaire (MSNQ) in natalizumab -treated 
MS patients over 48 weeks. Mult Scler. 2010;16(11):1385-92.
Oturai AB, Koch- Henriksen N, Petersen T, et al. Efficacy  of natalizum ab in multiple sclerosis 
patients with high disease activity : a Danish nationwide study . Eur J Neurol. 2009;16(3):420-3.
Sangalli F, Moiola L, Bucello S, et al. Efficacy  and tolerability  of natalizumab in relapsing –
remitting multiple sclerosis patients: a post-marketing observational study. Neurol Sci. 
2011;31(0):299 -302.
Schumacher G, Beebe G, Kibler R, et al. Problems of experimental trials of therapy  in multiple 
sclerosis: Report by  [CONTACT_328942] y in Multipl e 
Sclerosis. Ann NY Acad Sci. 1965;122(1):552-568.
Sormani MP, Bruzzi P. MRI  lesions as a surrogate for relapses in multiple sclerosis: a meta -
analysis of randomised trials. L ancet Neurol. 2013;12(7):669 -76.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagn osis of multiple sclerosis: 2017 revisions of 
the McDonald criteria. Lancet Neurol. 2018;17(2):162- 173. Epub 2017/12/21.
Protocol 101MS329 Version 4.[ADDRESS_406340] read the foregoing protocol, “A Randomized, Controlled, Open -Label, Rater -Blinded, 
Phase3b Study  of the Efficacy , Safet y, and Tolerability  of 6-Week Extended Interval Dosing of 
Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching 
From Treatment With [ADDRESS_406341] Interval Dosing (SID) in Re lation to 
Continued SI D Treatment -Followed b y an Open -Label Crossover Extension Study  Comprising 
Subcutaneous and Intravenous Natalizumab Administration ” and agree to conduct the study  
according to the protocol and the applicable ICH guidelines and GCP r egulations, and to inform 
all who assist me in the conduct of this study  of their responsibilities and obligations.
____________________________________________________
Investigator’s Signature         [CONTACT_1782] (dd -MONTH -yyyy)
____________________________________________________
Investigator’s Name (Print)
____________________________________________________
Study  Site (Print)
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
1Biogen MA Inc.
225Binney Street
Cambridge, MA  [ADDRESS_406342]
Maidenhead, Berkshire
SL6 4AY
[LOCATION_008]
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol 101MS329
A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b Study  of the Efficacy , 
Safety , and Tolerability  of 6 -Week Extended Interval Dosing (EID) of Natalizumab (BG00002) 
in Subjects With Relapsing -Remitting Multiple Sclerosis Switching From Treatment With 
4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment -
Followed b y an Ope n-Label EID Crossover Extension Study  Comprising Subcutaneous and 
Intravenous Natalizumab Administration
Version 4.0
Date: 20August [ADDRESS_406343] Number: 2018 -002145 -11
Version 4.0of the protocol has be en prepared for this amendment, which supersedes Version 3.0.

Amendment Summary for Protocol 101MS329 , Version 4.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
2PRIMARY REASON FOR A MENDMENT
The primary  reason for this amendment to Protocol 101MS329 is the addition of detail s
regarding the S creening visit for new participants who did not participate in Part 1 of the study  
and are being enrolled in Part2.
New text is shown in bold ty pe; deleted text is shown with a strikethrough .
Section 5.2, Part 2 - Schedule of Activities, Table 4, footnote 1
Now reads:
1The Part [ADDRESS_406344] 
prestudy dose of natalizumab (see footnote 7). All other screening assessments can 
occur any time between the day of the last prestudy natalizumab dose and baseline.
Randomization to crossover study  treatment should be done at the Week 108 visit to confirm 
crossover treatment allocation.
Rationale: The change was made to c larify  the timing of the last prestudy  dose of natalizumab
and screening 
requirements for new participants being enrolled in the open -label extension , as 
well as 
the assessment sthat must be completed prior to the last prestudy  dose of natalizumab.
Amendment Summary for Protocol 101MS329 , Version 4.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
3SUMMARY OF MAJOR CHANGES TO THE PROTO COL
Changes to the protocol are presented chr onologically . New text is shown in bold type; deleted 
text is shown with a strikethrough.
Section 5.1, Part 1 - Schedule of Activities, Table 1
Change: In footnote 16 , instructions for postdosing observation requirements were revised
Now reads:
16Subjects must be observed for 1 hour after completion of infusion. Please refer to the 
Directions for Handling and Administration (DHA) located in the Study Reference 
Guide for details of postdose observation requirements.
Rationale: Biogen has elected to specify  requirements for postdosing observation in the D HAof 
natalizumab rather than the study  protocol.
This change also affects Section 5.1, Part 1 - Schedule of Activities (Table 2, footnote 16) ; 
Section 5.2, Part 2 
-Schedule of Activities (Table 3 , footnote 12); Section 5.2, Part 2 - Schedule 
of Activities (Table 4, footnote 13) ; and Section 11.3, Precautions.
Section 5.2, Part 2 - Schedule of Activities, Table 4
Change: The Nominal Study  Day for the Screening visit wasrevised.
Now read s:
-4142 to - 1
Rationale: This revision was required to align with the change in footnote 1 of this table .
Section 5.2, Part 2 - Schedule of Activities, Table 4
Change: Reference to footnote 7 was added to the Blood Chemistry assessment schedule .
Now read s:  
Blood Chemistry8,7
Rationale: The need for reference to footnote 7 was overlooked in the previous version.
Amendment Summary for Protocol 101MS329 , Version 4.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
4SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate :
The version number and date were updated throughout the protocol.
The Sponsor Signature [CONTACT_328952] .
Amendment Summary for Protocol 101MS329 , Version 4.[ADDRESS_406345]
Maidenhead, Berkshire
SL6 4AY
[LOCATION_008]
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol 101MS329
A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b Study  of the Efficacy , 
Safety , and Tolerability  of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) 
in Subjects With Relapsing -Remitting Multiple Sclerosis Switching From Treatment With 
4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment -
Followed b y an Ope n-Label EID Crossover Extension Study  Comprising Subcutaneous and 
Intravenous Natalizumab Administration
Version 3
Date: [ADDRESS_406346] Number: 2018 -002145-11
Version 3
of the protocol has be en prepared for this amendment, which supersedes Version 2.

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
2PRIMARY REASON FOR A MENDMENT
The primary  reason for this amendment to Protocol 101MS329 is the addition of an OLE 
comprising a crossover analy sis of natalizumab administered by  [CONTACT_328943] .
New text is shown in bold ty pe; deleted text is shown with a strikethrough .
Section 7, Study Design
Now reads:
This study will be conducted in [ADDRESS_406347] assignment. Approximately  
480 subjects are expected to be enrolled at approximately  100 sites in North America, Europe, 
and Australia. Subjects will be randomly  assigned to continue to receive natalizumab in 1 of the 
following 2 arms groups:
SID:approximately  240 subjects will receive natalizumab as a 300 mg IV infusion 
every  4weeks (28 [-2/+5 day s]).
EID:  approximately  240 subjects will receive natalizumab as a 300 mg IV infusion 
every  6weeks (42 [-2/+5 day s]). 
Randomization will be stratified b y countr y/region (North America [includes [LOCATION_003] and Canada], 
[LOCATION_008], Europe and Israel [includes Belgium , [LOCATION_009], German y, Israel, Ital y, 
Netherlands, and Spain], and Australia), bod y weight ( ≤ 80 kg versus > 80kg), and duration of 
natalizumab exposure ( ≤ 3years versus > 3years). Subjects will receive open -label natalizumab 
at their assigned frequency  throughout the [ADDRESS_406348] not to participate, in Part 2 will enter a 12- week follow -up, and will 
receive a follow -up safety phone call 12 week
s later (i.e., [ADDRESS_406349] dose of 
study treatment ) before completing the study.
See Figure 1for a schematic of the study  design.
Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
3Figure 1: Study Design
Part [ADDRESS_406350] 12 months , may also be enrolled in Part 2 
as 
new subjects to en sure adequate sample size for the Part 2 analysis.
Subjects enrolled in Part 2 will receive natalizumab 300 mg by [CONTACT_28776] 
6weeks (42 ±7 days) for a period of 36weeks and be randomized to an additional 48 weeks 
of crossover treatment comprising 24 weeks EID SC Q6W and 24 weeks EID IV Q6W. All 
MRI scans will be read at a central facility by [CONTACT_211489].
At the completion of their 48 -week crossover treatment period, subjects in Part 2 will 
receive a final dose of natalizu mab 300 mg by [CONTACT_328944] 156, proceed to the12-
week follow -up, and receive a further safety follow -up by [CONTACT_756] 12 weeks later (i.e., 
24weeks after the last dose of study treatment ) before completing the study.
The design of this study, inclu sive of Parts 1 and 2, is presented in Figure 1.

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
6…
15The screening MRI must be performed at least [ADDRESS_406351]'s MRI is scheduled to occur <[ADDRESS_406352] MRI was perform ed within the previous 4 weeks. In the event of an 
early study term ination for a pregnancy, a Gd -enhancing MRI should not be conducted.
In Section 5.2 :
Introductory text was added to Section 5.2, Part 2 – Schedule of Activities .
Table 3: Part 2 Schedule of Activities – EID SC vs .IV OLE for Subjects Who 
Participated in Part 1was added, with supporting footnotes.
Table 4: Part 2 Schedule of Activities – EID SC vs .IV OLE for New Su bjects was 
added ,with supporting footnotes.
Now read s:
5.2. Part 2 –Schedule of Activities
For subjects who completed Part 1 treatment and enrolled in Part 2, the schedule of 
activities for Part 2 (Table 3) does not differ for subjects randomized to SC/IV or IV/SC 
with the exception of the order of treatment administration during the crossover period.
For new subjects enrolled in Part 2, the initial screening, inclusive of select assessments, 
differs from those subjects who participated in Part 1 but is 
otherwise the same beginning 
at Week 78 through the end of Part 2 (Table 4 ).
Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
7Table 1: Part 2 Schedule of Activities –EID SC vs . IV OLE for Subjects Who Participated in Part 1
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed as follows : 
 2) clinical and neurological assessments, 3) PK/PD  collection, and 4) dose administration. It is not 
required that all screening tests and assessments be completed during 1 visit.
Study Week 78 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit2Unscheduled Visit
(Neurological 
Worsening and 
Relapse 
Assess ment)3Follow -Up 
Safety 
Phone Call
1804
Study Day546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Informed 
Consent Form 
for Part 25----X ----
Eligibility 
Criteria Check 
for Part 25----X ----
Randomization X
Vital signs6X X X X X X X X X X X X X X X X
Physical 
Exam ination1 X X X X X X X
Body Weight1X X X X
C-SSRS1,7X
TSQM X X X
EDSS X X X X X X

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
8Study Week 78 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit2Unscheduled Visit
(Neurological 
Worsening and 
Relapse 
Assess ment)3Follow -Up 
Safety 
Phone Call
1804
Study Day546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Neurological 
Exam ination 
(MS Signs & 
Sym ptoms)X X X X X X
Blood 
Hematology8 X X X X X X X
Blood 
Chemistry9 X X X X
Urine Pregnancy 
Test10
PD Assessments 
(whole blood)8 X X X X X X X X X X
PK Natalizumab 
Concentration 
(serum)8X X X X X X X X X X
Anti -
natalizumab 
Antibodies8X X X X X X
Brain MRI11X X X X
Natalizumab 
EID IV infusionX X X X X X

Amendment Summary for Protocol 101MS329 , Version [ADDRESS_406353]'s standard of care on the sam e day as a study visit do not need to be repeated f or the study if Biogen has 
access to the inform ation and data recorded in the subject's CRF. Vital signs on a study treatm ent day must be performed prior to the 
administration of study treatm ent.
7The Part 1 "baseline/screening" C- SSRS must be completed at the Part 1 screening Visit; at all other visits, the "since las t visit" C- SSRS must be 
used.
8Sample to be collected prior to dosing.
9If a subject experiences signs and symptoms suggestive of liver failure (such as jaundice, vom iting, anorexia, nausea, fatigu e, and right upper 
abdominal discom fort), liver function tests (alanine am inotransferase, aspartate am inotransferase, alkaline phosphatase, gamm a-glutamyl 
transferase, bilirubin, and albumin) must be perform ed at the local laboratory on an expedited basis.
10Follow -up testing for wom en of childbearing potential throughout the study will be done at the discretion of the Investigator or as required by [CONTACT_49762]. In each case of delayed menstruation (more than 1 month between menstrual periods ), a urine pregnancy test should be perform ed.
11All postbaseline MRIs a re to be com pleted within a [ADDRESS_406354]'s MRI is scheduled to occur < 4weeks after the last 
dose of steroid treatm ent for relapse, the MRI should be rescheduled so it is performed either before the steroid treatm ent o r between [ADDRESS_406355]’s choice.
14PPQ assessments at Week [ADDRESS_406356] be collected after study treatm ent adm inistration.
Amendment Summary for Protocol 101MS329, Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published without the written consent of Biogen MA Inc.
11Table 2: Part 2 Schedule of Activities – EID SC vs. IV OLE for New Subjects
Tests and assessments are listed in the recommended order. At each visit, assessments should be performed as follows:  
, 2) clinical and neurological assessments, 3) PK/PD  collection, and 4) dose administration. It is not 
required that all screening tests and assessments be completed during 1 visit. This Schedule of Activities is identical to the Schedule in Table 3 after the Week 84 visit.
Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow-
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment)4Follow-
Up Safety 
Phone 
Call5
180
Nominal
Study Day-41 to -
1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)--1260
(±10)
Informed
Consent Form 
for Part 21X
Eligibility 
Criteria Check 
for Part 21XX
Randomization X
Medical History
1 X
Physical Examination
1 XX X X X X X X X
Body Weight1XX X X X X
Vital signs6X X X XXXXXXXXX X X X X X X
HIV, Hep B, and 
Hep C TestingX
TSQM X X X XP
D
Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
12Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assess ment)4Follow -
Up Safety 
Phone 
Call5
180
Nominal
Study Day-41 to -
1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
EDSS X X X X X X X
Neurological 
Exam ination 
(MS Signs & 
Sym ptoms)X X X X X X X
Blood 
Hematology7 X X X X X X X X
Blood 
Chemistry8 X X X X X
Serum 
Pregnancy Test9 X
Serum FSH10X
Urine Pregnancy 
Test11 X
PD Assessments 
(whole blood)7 X X X X X X X X X X X
PK Natalizumab 
Concentration 
(serum)7X X X X X X X X X X X
Anti -
natalizumab 
Antibodies7X X X X X X X

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
13Nominal
Study WeekScreen1Baseline 
Visit
7278 [ZIP_CODE] 96 102 108 114 120 126 132 138 144 150 156Follow -
Up EOS 
Visit
168ET 
Visit3Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assess ment)4Follow -
Up Safety 
Phone 
Call5
180
Nominal
Study Day-41 to -
1504
(-2/
+5)546
(-2/
+5)588
(-2/
+5)630
(-2/
+5)672
(-2/
+5)714
(-2/
+5)756
(-2/
+5)798
(-2/
+5)840
(-2/
+5)882
(-2/
+5)924
(-2/
+5)966
(-2/
+5)1008
(-2/
+5)1050
(-2/
+5)1092
(-2/
+5)1176
(±10)- -1260
(±10)
Brain MRI12X X X X X
Natalizumab 
EID IV infusionX X X X X X X
Natalizumab 
EID SC -IV 
Crossover13X X X X X X X X X14
PPQ14X X X
Safety (AEs, 
SAEs)Record as per Section 15.[ADDRESS_406357] as per Section 11.5 of the protocol X
Assess ment of 
New 
Neurological 
Sym ptoms15X
AE=adverse event; CRF = case report form ; EDSS = Expanded Disability Status Scale; EID = extended interval dosing; EOS =end of study; 
 ET=early termination; FSH = follicle stimulating hormone; Gd = gadolinium; Hep = hepatitis; HIV = 
human immunodeficiency virus; IV=intravenous ; MRI =magnetic resonance im aging; MS = m ultiple sclerosis;  
; OLE =open -label extension; PD =pharmacodynamic; PK =pharm acokinetic; PPQ = Patient Preference 
Questionnaire; SAE = serious adverse event; SC = subcutaneous; Sg = Screening; TSQM =Treatm ent Satisfaction Questionnaire for Medication.

Amendment Summary for Protocol 101MS329 , Version [ADDRESS_406358] dose of study 
treatm ent, to be followed by a final EOS Visit at 12 weeks ( ±10 days) and the safety follow -up phone call at [ADDRESS_406359] within 5 days of the onset of sym ptoms. Relapses should 
be documented in the relapse assessment form. The maximum number of samples eligible for collection and analysis are 2 (1 for each unscheduled 
visit).
5Subjects should have a follow -up safety phone call [ADDRESS_406360]'s standard of care on the sam e day as a study visit do not need to be repeated for the study if Biogen has 
access to the inform ation and data recorded in the subject's CRF. Vital signs taken on a study treatm ent day must be pe rform ed prior to the 
administration of study treatm ent.
7Sample to be collected prior to dosing.
8If a subject experiences signs and symptoms suggestive of liver failure (such as jaundice, vom iting, anorexia, nausea, fatigu e, and right upper 
abdominal di scom fort), liver function tests (alanine am inotransferase, aspartate am inotransferase, gamm a-glutamyl transferase, bilirubin, and 
albumin) must be performed at the local laboratory on an expedited basis.
9Required for wom en of childbearing potential. Resu lts must be known prior to Baseline.
10For postm enopausal subjects only.
11Follow -up testing for wom en of childbearing potential throughout the study will be done at the discretion of the Investigator or as required by [CONTACT_49762]. In each case of delayed menstrua tion (more than 1 month between menstrual perio ds), a urine pregnancy test should be perform ed.
12The screening MRI m ust be perform ed at least [ADDRESS_406361]'s MRI is scheduled to occur < [ADDRESS_406362]’s choice.
15PPQ assessments at Week [ADDRESS_406363] dose of study treatm ent to discuss if there has been any new de velopm ent of 
neurological symptoms. PML or new neurological symptoms indicative of PML (new or s udden change in thinking, vision, balance, or strength 
persisting over several days) must be immediately reported as a SAE.
Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
17To evaluate the efficacy of SC versus IV 
routes of natalizumab administration.All endpoints will be assessed between 
6months of SC and 6 months IV in the 
randomized, crossover period.
Number of new or newly enlarging 
T2hyperintense lesions
Time to first relapse
Annualized relapse rate
Change in EDSS score
Number of new Gd -enhancing lesions
Number of new T1 hypointense lesions
PBVC and cha nge in cortical and 
thalamic brain region volume
To characterize PK and PD of SC versus 
IV routes of natalizumab administration.All endpoints will be assessed between 
6 months of SC and 6 months IV in the 
randomized, crossover period.
Ctrough
Trough α4 integrin saturation

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
18Rationale: The objective of the OLE is to evaluate subject preference for, and satisfaction, with 
SC injection and IV infusion of natalizumab under EID , and to develop long -term efficacy  and 
safet y data with regard to natalizumab administration in general under the EIDregimen.
This change also substantially affects Section 13, Efficacy , Pharmacokinetic, and 
Pharmacod ynamic Assessments; and Section 16, Statistical Methods and Determination of 
Sample Size.
Section 7.1, S tudy Duration for Subjects
Change: Section 7 was revised to comprise Section 7.1.1, Study  Duration for Subjects Enrolled 
Only  in Part 1, and Section 7.1.2, Study  Duration for Subjects Enrolled in Part 1 and Part 2 . 
Now reads:
7.1.1. Study Duration for Subjects Enrolled Only in Part [ADDRESS_406364] s who do not participate in 
Part 2will be up to 102 weeks ;.tThis consists of comprises a screening period of up to 
6weeks ,;a treatment period of 72 weeks ,;and afollow -up period of 12 weeks ; and .  Aa
follow -up safet y phone call will b e performed 2412weeks after the follow -up period 
(i.e., 24weeks after the last dose of study  treatment) .
The end of stud y (EOS) date for a subject in Part [ADDRESS_406365] protocol -specified assessment ,;or if the subject has 
ongoing AEs that are being followed up, then the date may  be the date of AE resolution.
7.1.2 Study Duration for Subjects Enrolled in Part 1 and Part 2
The total duration of study participation in Part 1 for subjects who also participate in Part 
2 will be up to 78 weeks, comprising a screening period of up to 6 weeks and the 
randomized SID or EID treatment period of 72 weeks.

Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
19The total duration of study participation in Part 2 for these subjects will be approximately 
108 weeks . This comprises EID IV treatment for 36 weeks; a randomized EID SC vs .IV 
crossover -treatment period of 48 weeks; a follow -up period of 12 weeks; and a follow -up 
safety phone call 12 weeks after the follow -up period (i.e., [ADDRESS_406366] dose of 
study treatment).  The total duration of study participation for subjects who participate in 
both Part [ADDRESS_406367] protocol -specified assessment; if the subject has ongoing 
AEs that are being followed, then the date may be the date of AE r esolution.
Rationale: Revision of this section was required to differentiate the duration of study  for 
subjects who participate in Part 1 only, in both Part 1 and Part 2, a s well as for new subjects who 
participate in Part 2 of the study  without having participated in Part 1.
This change also substantially affects Section 7.3, 
Unscheduled Visits and Treatment for MS 
Relapses; Section 7.5, End of Study ; Section 9, S creening and Randomization; Section 10, 
Discontinuation of Study Treatment and Withdrawal o f Subjects from the Study ; andSection 11, 
Study Treatment Use .
Amendment Summary for Protocol 101MS329 , Version 3
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
20SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate :
The title, version number , and date were updated throughout the protocol.
Section 2, L ist of Abbreviations, was updated.
In Section 4.2, c urrent therapi[INVESTIGATOR_328908].
Typographical errors and formatting were corrected.
Amendment Summary for Protocol 101MS329, Version [ADDRESS_406368] OF ABBREVIATIONS
AE adverse event
CRF case report form
C-SSRS Columbia Suicide Severity Rating Scale
Ctrough trough serum concentration of natalizumab
DNA deoxyribonucleic acid
EDSS Expanded Disability Status Scale
EID extended interval dosing
EOS end of study
ET early termination
FSH follicle stimulating hormone
Gd gadolinium
Hep hepatitis
HIV human immunodeficiency virus
IV intravenous(ly)
JCV John Cunningham virus
MRI magnetic resonance imaging
MS multiple sclerosis
OLE open-label extension
PBMC peripheral blood mononuclear cell
PBVC percentage of brain volume change
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PML progressive multifocal leukoencephalopathy
PPQ Patient Preference Questionnaire
PRO patient-reported outcome
Q4W every [ADDRESS_406369]
Maidenhead Berkshire
SL6 4AY
[LOCATION_008]
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol 101MS329
A Randomized, Controlled, Open -Label, Rater -Blinded, Phase 3b Study  of the Efficacy , Safety , 
and Tolerabilit y of 6 -Week Extended I nterval Dosing of Natalizumab (BG00002) in Subjects 
With Relapsing -Remitting Multiple Sclerosis Switching From Treatment With [ADDRESS_406370] Interval Dosing (SID) in Relation to Continued SI D Treatment
Version 2.0
Date: 28February  [ADDRESS_406371] Numbe r: [ADDRESS_406372] 12 months, in 
relation to continued SID treatment.and Week 7248
Number of new gadolinium 
(Gd) -enhancing and new 
T1hypointense lesions at Weeks 24, 
48, and 72
… …
Rationale: The timing of the primary  efficacy  endpoint was changed to Week [ADDRESS_406373] 1 postbaseline efficacy  assessment, will be used for 
all efficacy  anal yses.  Subjects will be anal yzed in the groups to which they are randomized.
16.1.2. Methods of Anal ysis
[IP_ADDRESS]. Analy sis of the Primary  Endpoint
The primary  endpoint, the number of new or newly  enlarging T2 hyperintense lesions at 
Week 4872, will be ana lyzed using negative binomial regression models with treatment as the 
classification variable and baseline bod y weight ( ≤9080kg versus > 9080kg), EDSS, duration 
of natalizumab exposure at baseline (≤ 3 years versus > 3 years), and region (North America 
[includes [LOCATION_003] and Canada], [LOCATION_008], Europe and Israel [includes Belgium, 
[LOCATION_009], [LOCATION_013], Israel, Italy, Netherlands, and Spain], and Australia) as covariates.  The 
ratio of mean lesion numbers of EID versus SID (EID/SID) will be derived from the mod el with 
a 95% CI and associated p-value.  The treatment will be considered different if the p value 
(2sided) is less than 0.05.  The lower limit of the 95% CIisabove 1.  As a secondary 
inference, the possibility  of a 2 -fold increase in the mean lesion nu mber in the EID group as 
compared with the SID group will be considered ruled out if the upper limit of 95% CI  is lessno 
greater than 2.  The proportion of subjects with no new or newly  enlarging T2 hyperintense 
lesions will be analy zed using logistic regr ession models with the same covariates as those 
described above.
For subjects who withdraw or receive rescue SID natalizumab prior to Week 48, the Week 48 
number of lesions may be imputed using the MMRM.
[IP_ADDRESS]. Primary and Secondary Estimands and Handli ng of Intercurrent Events
The study plans to make every effort to retain subjects in the study and to continue 
follow -up in the cases of the initiation of rescue medication, switching to different dosing 
frequency, and treatment discontinuation due to AEs, lack of efficacy, or for other reasons.  
This will allow continuing assessments of subjects’ MS disease activity.  Ef forts will also be 
made to obtain details of withdrawals in the generic categories of “lost to follow -up” or 
“other” whenever possible.  Classification of the withdrawals in these nonspecific 
categories into “possibly efficacy related”, “possibly safety re lated”, or “no information” 
will be made based on all available information by [CONTACT_328945]. 
The proposed primary estimand will be based on a treatment policy strategy, in which the 
study is intended to estimate the difference of a potential treatment decision of switching 
subjects from SID to EID compared with keepi[INVESTIGATOR_328904] [ADDRESS_406374] a “possibly related” withdrawal , as described above, the missing values will be 
imputed by [CONTACT_328946].  For withdrawals classi fied as “no information”, the missing values will be 
treated as missing at random and will be addressed using multiple imputation.  The 
number and proportion of subjects with intercurrent events and the time to intercurrent 
event will also be tabulated and
compared between randomized groups.  Sensitivity 
analysis may be conducted using tippi[INVESTIGATOR_18275].  Supplementary analyses by 
[CONTACT_328947]. 
The secondary estimand will be based on a hypothetical strategy, in which the difference in 
the efficacy of EID versus SID over the [ADDRESS_406375] -intercurrent event as missing values.  For 
treatment discontinuation or switching due to efficacy as well as withdrawal that is due to 
efficacy or is “possibly efficacy related”, the missing values will be imput ed by [CONTACT_328948].  For intercurrent 
events due to other reasons, the resulting missing values will be addressed using multiple 
imputation.  Sensitivity analysis may be conducted using tippi[INVESTIGATOR_18275].
[IP_ADDRESS].1.2.3. Analy sis of the Secondary  Endpoints
…
Annualized Relapse Rate
The annualized relapse rate at Week 48 and Week 72 will be anal yzed at each timepoint using 
negative binomial regression models with treatment as the classification variable and baseline 
body  weight ( ≤9080kg versus > 9080kg), EDSS, duration of natalizumab exposure at 
baseline ( ≤ 3years versus > 3 years), and region (North America [includes [LOCATION_003] and 
Canada], [LOCATION_008], Europe and Israel [includes B elgium, [LOCATION_009], [LOCATION_013], Israel, 
Italy, Netherlands, and Spain], and Australia) as covariates.  The ratio of mean lesion 
numbers of EID versus SID (EID/SID) will be derived from the model with a 95% CI and 
associated p- value.
EDSS Worsening
Confirmed EDSS worsening is defined as an increase of at least 1.0 point from a baseline 
EDSS score ≥ 1.[ADDRESS_406376] 
relapse .
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
8…
16.7. Interim Anal yses
An interim futility  anal ysis, based on the number of new or newl y enlarging T2 hyperintense 
lesio
ns at 24 weeks, will be conducted when 50% of subjects have at least 6 months of 
randomized treatment.  The interim futility  anal ysis is designed to ensure that if clinically  
meaningful loss of efficacy  is occurring in the EID group, the study  can be stopp ed early  to 
prevent unnecessary  risk to the study  participants of uncontrolled MS disease activity  as a result 
of potential efficacy  failure on EID The interim data will be analyzed using negative binomial 
regression models with treatment as the classificat ion variable and baseline body weight 
(≤ 80 kg versus > 80 kg), duration of natalizumab exposure at baseline (≤ 3 years versus 
> 3 years), and region (North America [includes [LOCATION_003] and Canada], [LOCATION_008], 
Europe and Israel [includes Belgium, [LOCATION_009], Ger many, Israel, Italy, Netherlands, and 
Spain], and Australia) as covariates.  The ratio of mean lesion numbers of EID versus SID 
(EID/SID) will be derived from the model with a 95% CI.  The study may be stopped for 
futility if the lower limit of the 95% CI is >2and a 2- fold increase in mean lesion numbers 
in the EID group can be concluded with 97.5% confidence .
16.8. Sample Size Considerations
To detect an increase in the mean number of new or newl y enlarging T2 hyperintense lesions 
over 48 weeks at the alpha level of 0.05 (2 sided), a sample size of 400 subjects (200 subjects per 
arm) will provide the following:
>80% power to detect an increase from a mean of 0.3 (expected efficacy  of 
SIDdosing arm in this population) to 0.5.
≥90% power to detect an inc rease from a mean of 0.[ADDRESS_406377] little or no clinical 
relevance of a differenc e of 0.2 to 0.3 in mean lesion numbers over 72 weeks [Sormani and 
Bruzzi 2013] .  With the planned sample size of N =200/group, the precision of the 
estimated mean lesion numbers is sufficient to allow > 80% probability to observe the 
lower limit of the 95 % CI for the ratio of EID to SID in the estimated mean lesion number 
above 1 if the true mean is 0.5 and 0.3 in the EID and SID group, respectively.  If the true 
mean is 0.6 and 0.3 in the EID and SID group, respectively, the probability will be 
approximat ely 90%.  In the other direction, the sample size provides a precision that allows 
approximately 90% probability to observe the upper limit of the 95% CI to be ≤ 2 if the 
true mean lesion numbers in both groups are 0.3.   Approximately  480 subjects will be 
enrolled to account for a drop -out rate of approximately  17%.
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
9Rationale: The text describing the overview of st atistical analy sis for efficacy  in Section 16.[ADDRESS_406378] been reached. 
Stratification on the factor “country /region” was clarified per EMA re quest because it was not 
clear whether stratification would be based on regions, countries, or a mixture of the two. A 
lower cutoff for bod y weight (i .e.,80 kg) was used because at weight > 80 kg, a decrease in 
efficacy  was suggested based on the PK/PD modelling data and per EMA request. Duration of 
natalizumab exposure was added as a covariate in place of EDSS perEMA request and guidance 
that any  factor utilized in randomization stratification s hould also be utilized as a model 
covariate.  Detailed inference criteria for the primary  anal ysis were edited to avoid the potential 
misinterpretation that the study  was designed to test the superiority  of EID over SID and to better 
reflect the study  goal of estimating the difference between SID and EID, with high precision and 
a narrow 95% confidence interval (CI), to support the treatment decision based on individualized 
benefit/risk assessments, as discussed and agreed upon with the EMA.
The a nalysis plan was revised to include primary  and secondary  estimands based on International 
Council for Harmonisation E9 (R1) Draft Addendum on estimands 
EMA/CHMP/I CH/436221/[ADDRESS_406379] from the EMA that these statistical details be 
included in the protocol rather than onl y in the study  statistical analy sis plan.
With the primary  endpoint changed to Week 72, the corresponding secondary  endpoint timing 
was changed to Week 48 and there will no longer be an efficacy  analy sis performed at Week 48;
.
  EDSS 
worsening was further defined, consistent with thereprioritization of EDSS worsening as a 
secondary  endpoint. 
Time to EDSS worsening was prioritized as a secondary  endpoint;  
Subgroup analyses are useful for assessing heterogeneity  and might further stress or refute the 
need for individualized benefit/risk assessments .The EMA requested that information on 
prespecified subgro up analy ses be included in the protocol rather than only  in the statistical 
analysis plan.
Interim anal ysis text was updated to clarify  that the study  may  be stopped for a degree of inferior 
efficacy  that would discourage the use of EID in all settings. Consultation with leading 
neurologists treating MS led to an empi[INVESTIGATOR_328909] a change from 0.3 with SI D to 
0.6(a 2-fold increase) with EI D at a population level would represent an unacceptable disease 
activity  for considering EID as a reasonable PML  risk mitigation strategy . The EMA requested 
that details of the anal ysis planned for assessment of futility  be included in the protocol rather 
than only  in the statistical analy sis plan.
Sample size considerations were revised to avoid the potential misinterpretation that the study  
was designed to test superiority  of EID over SID and to better reflect the study  goal of esti mating 

Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
10the difference between SID and EID, with high precision and a narrow 95% CI , to support the 
treatment decision based on individualized benefit/risk assessments, as discussed and agreed 
upon with the EMA. Text was added to address the sample size ap propriateness for both the 
primary  and secondary  analy ses discussed with the EMA, i .e., to check if there is a difference 
between E ID and SID andto exclude the 
worsening of efficacy  with EID at a level that would 
discourage the use of EID in most clinical settings.
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
11SUMMARY OF MAJOR CHANGES TO THE PROTOCOL
Changes to the protocol are presented chronologically . New text is shown in bold type; deleted 
text is shown with a strikethrough.
Section 1, Synopsis
The Sy nopsis was revised to reflect changes made throughout the protocol.
Section 5, Schedule of Activities
Change: The s creening period was extended to Day s -42 to -1, and a new footnote (Footnote 1) 
was added to clarify  the screening timing. 
Week [ADDRESS_406380] experiencing signs and sy mptoms suggesti ve of liver injury .
Footnote 12 of Table 1 was updated to include language on delay ed menstrual period and 
pregnancy  testing. 
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
12Now reads:
Table 1: Schedule of Activities – SID
Study WeekScreening 
Visit
41
-6 to -1Baseline 
Visit
04 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 Follow 
Up 
EOS 
Visit
84Follow 
Up 
Safety 
Phone 
Call12
96 ET 
Visit23Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment)34
Study Day-2842 to -1 1 28
(-2/
+5)56
(-2/
+5)84
(-2/
+5)112
(-2/
+5)140
(-2/
+5)168
(-2/
+5)196
(-2/
+5)224
(-2/
+5)252
(-2/
+5)280
(-2/
+5)308
(-2/
+5)336
(-2/
+5)364
(-2/
+5)392
(-2/
+5)420
(-2/
+5)448
(-2/
+5)476
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
Informed Consent 
FormX
Eligibility Criteria 
CheckX X
Randomization X
Medical History X
Physical 
ExaminationX X45X X X X X X
Body  Weight X X45X X X X X X
Vital Signs56X X X X X X X X X X X X X X X X X X X X X X X
HIV, Hep B, and 
Hep C TestingX

Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
13Study WeekScreening 
Visit
41
-6 to -1Baseline 
Visit
04 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 Follow 
Up 
EOS 
Visit
84Follow 
Up 
Safety 
Phone 
Call12
96 ET 
Visit23Unscheduled 
Visit 
(Neurological 
Worsening 
and Relapse 
Assessment)34
Study Day-2842 to -1 1 28
(-2/
+5)56
(-2/
+5)84
(-2/
+5)112
(-2/
+5)140
(-2/
+5)168
(-2/
+5)196
(-2/
+5)224
(-2/
+5)252
(-2/
+5)280
(-2/
+5)308
(-2/
+5)336
(-2/
+5)364
(-2/
+5)392
(-2/
+5)420
(-2/
+5)448
(-2/
+5)476
(-2/
+5)504
(-2/
+5)588
(±10)672
(±10)
C-SSRS67X X X X X X X X X X X X X X X X X X X X X X X
EDSS X X X X X X X
Neurological 
ExaminationX X X X X X X
Blood 
Hem atology78X X X X X X
Blood Chemistry9X X X
Serum Pregnancy 
Test810X
Serum FSH911X
Urine Pregnancy 
Test1012X

Protocol 101MS329, Version 2.[ADDRESS_406381] experiences signs and symptoms suggestive of liver injury (such as jaundice, vomiting, anorexia, nausea, fatigue, and right upper 
abdominal discomfort), liver function tests (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma- glutamyl 
transferase, bilirubin, and albumin) must be performed at the local laboratory on an expedited basis.
10Required for women of childbearing potential.  Results must be known prior to Day 1/Baseline.
911For postmenopausal subjects only.
1012Required for women of childbearing potential.  Follow-up testing throughout the study will be done at the discretion of the Inv estigator or as required by 
[CONTACT_1769]. In each case of delayed menstrual period (over 1 month between menstruations), a urine pregnancy test should be performed.
1214The screening MRI must be performed at least [ADDRESS_406382]’s MRI is scheduled to occur less than <[ADDRESS_406383] dose of study treatment to discuss if there has been any new deve lopment of any new 
neurological symptoms.  PML or new neurological symptoms indicative of PML (e.g., new or sudden change in thinking, vision, bala nce, or strength persisting 
over several days) must be immediately reported as an SAE.P
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
17Rationale: The s creening period was extended to Day s -42 to -1 to improve logistics for sites in 
the collection of informed consents. 
EDSS and neurological examination assessments were added at Week 84 to confirm the 
Week 72 secondary  endpoint. Anti- natalizumab antibodies assessment at Week 60 was added to 
make the schedule co nsistent with the existing text in the protocol and the ICF. 
Footnote 9 of Table 1 was added to include information on the monitoring of liver function to 
make the global protocol consistent with the local protocol amendment required in [LOCATION_009] .
Footnote 12 of Table 1 was updated to include pregnancy  testing consistent with Heads of 
Medicines Agencies Clinical Trial Facilitation Group guidance and to make the global protocol 
consistent with the local protocol amendment required in the [LOCATION_006]. 
This change also affects Table 2, Schedule of Activities – EID, Figure 1, Study  Design, and 
Section 7.1, Study  Duration for Subjects .
Section 7, Study Design
Change: Text was updated to clarify  stratification on the factor “country /region” and to use a 
lower cut -off for body  weight . 
Now reads: Randomization will be stratified by  [CONTACT_1606] /region (North America [includes 
[LOCATION_003] and Canada], [LOCATION_008], Europe and Israel [includes Belgium, [LOCATION_009], 
[LOCATION_013], Israel, Italy, Netherlands, and Spain], and Australia) , body  weight (≤90 80kg 
versus > 9080kg), and duration of natalizumab exposure ( ≤ 3years versus > 3years).  Subjects 
will receive open -label natalizumab at their assigned frequency  throughout the 72 weeks of the 
study .
Rationale: Clarified stratification on the fa ctor “country /region” because it was not clear 
whether stratification would be based on regions, countries, or a mixture of the two. A lower 
cut-off for bod y weight (i .e., 80 kg) was used because at weight > 80kg,a decrease in efficacy  
was suggested bas ed on the PK/PD modelling data and per the request of the EMA . 
This change also affects Section 9.2 , Randomization, Section [IP_ADDRESS], Analy sis of the Primary  
Endpoint , and Section 
[IP_ADDRESS], Analy sis of the Secondary  Endpoints .
Section 11.6, Continuation of Treatment
Change: Text related to continuation of treatment after 72 -week randomized treatment period 
was clarified. 
Now reads: There is no provision to provide study  treatment after the study .  Natalizumab is 
available commerciall y and subjects/I nvestigators can continue Ty sabri treatment via a 
commercial source.   Once subjects have completed the randomized 72- week treatment 
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
19Now reads: Expectedness of all AEs will be determined by [CONTACT_328949]’s Brochure .
Rationale: This change was made for consistency in using the reference safet y information 
contained in the Investigator’s Brochure to determine the expectedness of all adverse events.
Section 15.4.2, Pregnancy
Change: Text relate d to reporting of pregnancy  events was updated. 
Now reads: The Investigator must report a pregnancy  occurring in a female subject between 
the first dose of study treatment and [ADDRESS_406384] dose of study treatment by 
[CONTACT_328950] 24 hours of the study  site staff becoming aware of 
the pregnancy .  Refer to the Study  Reference Guide’s Official Study  Contact L ist for complete 
contact [CONTACT_3031].  The I nvestigator or study  site staff must report the outcome of the 
pregnancy  to Biogen.  A pregnancy  is not considered an AE and should not be recorded in the 
AE CRF.
Rationale: Text was revised to specify  the pregnancy  events collection period. 
Section 15.5, Contraception Requirements
Change: Text related to contraceptio n for males and the donation of eggs/sperm for all subjects 
was removed.
Now reads :All women of childbearing potential and all men must ensure that highl y effective 
contraception is used during the stud y and for at least [ADDRESS_406385] dose of study  treatment.
For the purposes of this study , women who do not meet one of the following criteria a re 
considered to be ph ysiologically  capable of becoming pregnant and are, therefore, defined as 
women of childbearing potential:
Postmenopausal
o12 continuous months of natural (spontaneous) amenorrhea without an alternative 
medical cause 
o6weeks after surgical bilateral oophorectom y with or without hy sterectomy
Posthy sterectomy
Female surgical sterilization (e.g., bilateral tubal ligation)
For the purposes of the study , highl y effective contraception is defined as contraception that 
achieves a failure r ate of less than <1% when used consistently  and correctly , and includes the 
following:
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
20For females:
Established use of oral, intravaginal, or transdermal combined (estrogen and progestogen 
containing) hormonal methods of contraception associated with the i nhibition of 
ovulation.
Established use of oral, injected, or implanted progestogen -only hormonal methods of 
contraception associated with the inhibition of ovulation.
Placement of an intrauterine device or intrauterine hormone-releasing s ystem.
Bilateral tubal occlusion.
For males:
Vasectom y with negative semen anal ysis at follow up.
Sex with a woman who uses the methods described for females if she is of childbearing 
potential.
True abstinence, when this is consistent with the preferred and usual lifest yle of the subject, can 
be considered an acceptable method of contraception based on the evaluation of the Investigator 
who should also take into consideration the duration of the clinical stud y.  Periodic abstinence 
(e.g., calendar, ovulation, sy mptothermal, postovulation methods) and withdrawal are not 
considered acceptable methods of contraception.
Pregnancy  reporting is described in Section 15.4.2.
Rationale:   The deletions make this section consistent with the inclusion/exclusion criteria.
Protocol 101MS329 ,Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
21SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate:
The version number and date were updated throughout the protocol.
Typographical errors and formatting were corrected. 